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Qualitative Expression Analysis of Interferon Alpha Receptor in HCV infected 
Patients Resistant to Interferon Therapy 
Thesis Outline 
Background: Hepatitis C virus (HCV) is a leading cause of hepatocellular carcinoma 
(HCC) and cirrhosis. More than 3% of the world population and about 6% of 
Pakistanis are currently living with the virus (genotype 3 most prevalent).  Interferon 
alpha (IFN-α) plus ribavirin is widely used standard therapy for chronic HCV 
treatment all over the world but pegylated interferon along with ribavirin has higher 
response rate than that of standard interferon.  
Objective of the study: In this study focus has been on to evaluate IFN receptor 
subunit expression as a predictive factor for response to IFN therapy and disease 
severity in the population of Pakistan. The other objectives were to analyze the 
socioeconomic status of the infected individuals and their awareness level 
regarding risks factors of HCV prevalence in this region.   
Principal findings: It is found that forty six percent of the IFN resistant HCV infected 
patients expressed IFNAR1 mRNA. IFNAR2 and STAT1 were expressed by almost 
all patients. However, a significant difference is observed in age, BMI, liver enzyme 
levels, ultrasonic findings and liver histopathology of the patients with positive liver 
expression of IFNAR1 as compared to patients negative for IFNAR1 expression. HCV 
infected patients belong to low socio-economic strata of Pakistani population. It is also 
evident through our statistical data that most of the patients knew that main spreading 
cause is blood products as compared to other risk factors.  
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Conclusion: It is contended that IFNAR1 can be used as a predictor factor of response 
to IFN standard therapy as well as disease severity. Measures should be taken to 
educate people regarding possible risks of acquiring HCV on urgent basis. Policies 
should be approved at governmental level for timely diagnosis and prevention of this 
devastating virus. Socio-economic status should be considered another risk factor 
for HCV infection and future studies should target the low socio-economic groups for 
research and other policies making purposes. 
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Chapter 1 
INTRODUCTION 
1. Hepatitis C Virus 
a. Discovery of HCV 
From 1982 to 1988, ~6 years of exhaustive investigations at Chiron 
Corporation led to the discovery of hepatitis C virus (HCV), flavi-like virus. 
Subsequently, the research demonstrated that major cause behind parenteral 
transmission of non- A non-B viral hepatitis abbreviated as, NANBH was HCV around 
the globe infecting ~170 million people (Houghton, 2009) 
b. Classification 
The viruses have been classified on the basis of physical as well as biological 
criteria. David Baltimore devised a classification scheme of the viruses, more than 30 
years ago, based on the nucleic acid nature of the virus. The Baltimore classification 
system, a well-designed molecular algorithm for virologists, encompasses 6 classes of 
viral genome. The principles in the classification scheme help understand flow of 
genetic information with different configurations of the viruses (Racaniello, 2009).  
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Group: 
HCV belongs to class IV i.e., positive sensed single-stranded RNA viruses. 
Positive sense RNA can be directly translated to form proteins by host ribosomes 
(Nicolini et al., 2012) 
Family and Genus:  
HCV belongs to the family Flaviviridae (large group of viruses) comprising 3 
genera i.e., genus Flavivirus (e.g., yellow fever virus), genus Hepacivirus (e.g., 
hepatitis C virus), and genus Pestivirus (e.g., bovine virus diarrhea) (Beth et al., 2009). 
c. HCV: Structure 
Size of HCV particles ranges between 40 and 70 nm in diameter with core and 
envelope glycoproteins i.e., E1 and E2 the chief components. Presumably the envelop 
proteins i.e., E1 and E2 are anchored in lipid bilayer derived from the host cell which 
surrounds the nucleocapsid. Nucleocapsid is made of core protein (multiple copies) 
harboring the genomic RNA (Moradpour et al., 2007).  
d. HCV: Genome 
The HCV has single-stranded positive sensed RNA genome ∼10kb size. The 
RNA contains an open reading frame and 5’ and γ’ flanking regions contain 
untranslated regions (UTRs) as shown in the figure. The open reading frame contains 
information for viral protein, RNA synthesis as well as for coordination of both 
processes (Rehermann and Nascimbeni, 2005). 
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Fig 1: HCV Genome Structure (Taken from Rehermann et al., 2005) (Rehermann and 
Nascimbeni, 2005) 
In the host cell cytoplasm, HCV genome acts as mRNA and is directly 
translated through 5’ UTR Internal Ribosomal Entry Site (IRES). The HCV RNA does 
not enter the host cell nucleus. The open reading frame is translated as polyprotein 
which is then processed co- and post-translationally with the help of both cellular as 
well as viral proteases as follows:  
 Structural proteins  
o Core, envelope proteins(E1 and E2) and p7   
 Nonstructural proteins  
o NS2, NS3, NS4A, NS4B, NS5A, NS5B 
(Rehermann and Nascimbeni, 2005) 
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e. Replication 
Following protein synthesis and maturation, membrane-associated replication 
complex is formed by non-structural proteins and HCVRNA giving an appearance of a 
perinuclear membranous web. The replication complexes-mediated transcription of 
negative sensed RNA intermediates in turn generate progeny of positive sensed RNA. 
Genomic RNA along with capsid proteins assemble resulting in the formation of 
nucleocapsid which bud through intracellular membranes (Rehermann and 
Nascimbeni, 2005).  
 
Fig 2 HCV: Life Cycle (Taken from Moradpour et al., 2007) (Moradpour et al., 2007) 
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f. Genotypes 
HCV has high genetic variability. There are many classification systems used 
for HCV but the one by Simmonds is widely accepted that categorizes HCV in to 11 
genotypes with 80 subtypes (Alexopoulou, 2001). The HCV RNA-dependent RNA 
polymerase lacks proofreading activity which results in greater genetic variability as 
shown in the figure (Argentini et al., 2009).  
 
Fig 3: HCV Genetic variability 
Genotyping and serotyping techniques were used for HCV genotype 
determination. The genetic variability of HCV is significantly related to disease 
severity, prognosis, diagnosis, treatment response and it is the root cause behind failed 
efforts for HCV vaccine production. Low response to IFN-α/ IFN-α along with 
ribavirin has been associated with Genotype 1 and 4 infected HCV patients 
(Alexopoulou, 2001). 
g. Vaccination 
Different factors were behind failure to develop vaccines against HCV  
 Research tools availability 
 HCV variability 
Genotypes Subtypes Isolates Quasispecies 
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 Tissue tropism  
 Host selection 
Establishment of tissue culture system for HCV has enabled the generation of 
HCV in sufficient amounts for vaccine antigens and immunological bioassay. 
Nowadays, a number of vaccines have gone into animal as well as human clinical 
trials.  
The main objectives of therapeutic vaccines are;  
 Cytotoxic cell activation 
 Cross-genotype neutralizing antibodies production 
Due to HCV genetic variability, vaccination, anti-HCV treatment or immune 
modulation can be used in combination. Most of the vaccines are in preclinical stage, 
some are in phase I/ II trials (Yu and Chiang, 2010).  
2. Hepatitis C 
The clinical features of hepatitis C are summarized in table 1:  
a. Epidemiology worldwide 
It has been estimated that ~γ% i.e., 170 million of world’s population is victim 
of HCV. Most of the countries have HCV infection prevalence less than 3%, some 
countries of Africa and Asia have even  higher prevalence as shown in figure 4 
(Holmberg, 2012).  
b. HCV Genotypes Epidemiology 
The geographical distribution of HCV genotypes is distinctive globally as 
shown in the table 2 (Negro and Alberti, 2011). 
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Table 1. Hepatitis C: Clinical features (Taken from (Rehermann and 
Nascimbeni, 2005))  
 Feature Hepatitis C 
Public-health impact 
Worldwide 170 million people infected 
Clinical course of infection 
Vertical/perinatal  transmission Rare 
Horizontal transmission Intravenous drug use, parenteral, sexual 
Chronic hepatitis: Histological 
characteristics   
Lymphoid aggregation and organization  same like primary 
lymphoid follicles; steatosis (with HCV genotype 3); 
reactive changes in epithelium of bile ducts 
Disease progression 
Liver cirrhosis 5–10% after 10 years of infection 
Hepatocellular carcinoma 
(HCC) 
In western world, HCC incidence (5-year cumulative) in 
cirrhosis patients is 17%, in Japan the incidence is 30%;  In 
Europe and USA , 3.7 per 100 person years in cirrhosis 
patients ; in Japan it is 7.1 per 100 person years in cirrhosis 
patients 
Preventive vaccination No 
Therapy  Pegylated interferon-α in combination with ribavirin; 
treatment response in 45–80% of cases, HCV genotype 
major factor 
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Fig 4: Hepatitis C: Worldwide Epidemiology (Taken from (Holmberg, 2012))
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 Table 2: Prevalence of HCV and distribution of genotypes (Taken from (Negro and Alberti, 2011))
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c. Epidemiology in Pakistan 
Pakistan has 6% HCV prevalence in its population (Khan et al., 2013) with 
genotype 3 predominant (Attaullah et al., 2011). The top three risk factors associated 
with HCV in Pakistan are Syringe/needle reuse (61.45%),  Surgery/dental work 
(10.62%) and Blood transfusion (4.26%) (Sievert et al., 2011).  
In Pakistan, HCV genotype 1 has 7.03% prevalence, genotype 2 has 3.81%, 
genotype 3 has 78.96%, genotype 4 has 1.59%, genotype 5 has 0.10%, genotype 6 has 
0.13%, mixed genotypes have 5.03% and untypeable genotypes have 3.30% 
prevalence. The predominant genotype is 3a with 55.10% prevalence rate followed by 
genotype 1a (10.25%), 3b (8.20%) and mixed genotype (5.08%) with respect to 
prevalence rate whereas genotypes 4, 5 and 6 were not frequent. Genotype 3 is 
predominates in all provinces. In Punjab province, genotype 1 is second most frequent 
genotype whereas in provinces Sindh, Balochistan and Khyber Pakhtunkhwa, the 
untypeable genotypes are the second most frequent genotypes (Attaullah et al., 2011). 
13 
 
 
Fig 5: HCV Genotypes Distribution in Pakistan (Taken from (Attaullah et al., 2011)) 
 
 Fig 6: Province Wise HCV Genotypes Distribution in Pakistan (Taken from 
(Attaullah et al., 2011)) 
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d. Signs and symptoms 
Most of the HCV infected patients i.e., 60%–75% show no symptoms. In case 
of symptomatic acute infections, the symptoms include jaundice, fatigue, malaise, 
anorexia, lethargy, abdominal pain, arthralgia, mild hepatosplenomegaly and maculo-
papular rash. These symptoms may persist for 2–12 weeks. Fulminant hepatitis is very 
uncommon in acute infection stage (Wong and Lee, 2006). 
e. How Hepatitis C spreads? 
Blood products are the main source of transmission of Hepatitis C. Besides 
this, sharing contaminated needles (e.g., injection drug users), reuse of contaminated 
syringes/ medical equipment, hemodialysis, surgery and infected sex partner can 
spread HCV infection (Wilkins et al., 2010). In Punjabi population the risk factors for 
HCV transmission include therapeutic injections (44.3%), dental surgery (16.6%), 
Blood contact or transfusion (10.7%), shaving at barbers shop/ sharing blades (5.9%), 
surgeries/ medical procedures (3.3%), multiple risk factors (9%), sporadic (4.9%) and 
others (5.4%) (Mujtaba et al., 2011). Mother to child transmission ranges from 2-8% 
(Prasad and Honegger, 2013). No evidence was found about association of casual 
contacts or sharing utensils with transmission of HCV (Lo Re and Kostman, 2005). 
Sneezing and coughing are also not the sources of HCV transmission (Arend, 2000). 
Oral fluid mode of HCV transmission is a controversy (Suzuki et al., 2005) but Saliva 
has been found positive for HCV in many studies (Arend, 2000, Suzuki et al., 2005).  
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f. Treatment 
IFN-α along with ribavirin is currently a standard treatment for HCV but the 
therapy is successful in ~50% of the patients with adverse affects. Through next 
decade, the pegylated IFN-α will stay base for anti-HCV treatment because of the fact 
that new formulations of IFN are not superior to this one or are in early developmental 
stages.  Partial antiviral activity has been demonstrated by antivirals that act directly 
and hence are not adequate to be used as monotherapy (Vezali et al., 2011).  
The combination of Peg-IFN-αβb/ Peg-IFN-αβa with ribavirin which has 
successful therapeutic response in 40–50% of HCV genotype 1 or 4 infected patients 
and 75–90% in HCV genotype 2 or 3 infected patients. The side effects commonly 
associated with this therapy includes reduced life quality resulting in dose reduction/ 
discontinuation in some patients (Sulkowski et al., 2011).  
As the HCV treatment has difficulties both physically and economically with 
failure rate in about 50% of the patients, this marks the importance of understanding 
the underlying mechanism in interferon resistance or non-response to therapy. 
Identification of factors behind non-responsiveness can be helpful in response 
prediction for the treatment. Resistance to therapy is the result of different factors 
including viral factors, host factors and HCV proteins induced molecular mechanism 
that inhibits IFN signaling cascade (Asselah et al., 2010).  
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3. Interferon 
Isaacs and Lindenmann discovered interferon- α/ȕ (IFN- α/ȕ) in 1λ57. It is a 
family of cytokines playing critical role in innate immunity regulation through its 
pleiotropic actions on almost all types of somatic cells. Humans express about 20 IFN- 
α subtype genes along with individual genes that encode IFN –ȕ, -ț, -ω and –ε (Huber 
and Farrar, 2011) . In humans, Interferons (IFNs) are key physiological regulators 
playing important role in biological functions with excellent pharmacological 
properties against a number of diseases e.g., viral infections and malignancies (Uddin 
and Platanias, 2004). 
a. Interferons and Interferon Receptors: Classification   
There are two major groups of IFNs i.e., type I and  type II interferons. Type I 
interferon include IFNα, IFNȕ and IFNω whereas type II interferons include IFNȖ. 
Genes encoding type I IFNs are located on chromosome λ. Structurally, IFNα, IFNȕ 
and IFNω have significant homology with each other and minimal homology with 
IFNȖ. All interferons bind to specific cell surface receptors hence initiating their 
biological effects. Type I IFNs bind specifically to type I IFN receptor whereas type II 
IFNs binds to type II IFN receptor. The type I IFN receptor (IFNR) consists of two 
subunits i.e., IFNAR1 and IFNAR2. IFNAR1 is 110 kDa in molecular mass whereas 
IFNAR2 has two different forms because of differential splicing of same gene i.e., 
IFNAR2c form (90-100 kDa) and IFNAR2b form (51 kDa). Type II IFN receptor 
consists of two subunits i.e., IFNGR1 (90 kDa) and IFNGR2 (62 kDa). Type I IFN 
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signal transduction mediates multiple biological functions such as Immunomodulation, 
differentiation, apoptosis, anti-angiogenic effect, cell cycle arrest, anti-viral effects, 
anti-tumor effect and protein synthesis as shown in Figure (Uddin and Platanias, 
2004).  
 
Fig 7. Type I IFN mediates multiple biological functions (from (Uddin and 
Platanias, 2004) 
b. Induction and Regulation of interferon 
Cells of the innate immune system i.e., macrophages and dendritic cells (DCs) 
sense pathogens through their pattern-recognition receptors (PRRs) and produce type I 
IFNs.  Plasmacytoid DCs (pDCs) particularly produce IFNα in large quantities 
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whereas non-immune cells i.e., epithelial cells and fibroblasts produce IFNȕ 
predominantly. Type I IFNs limit infectious agents spreading through induction of 
IFN-stimulated genes (ISGs) expression in infected and neighbouring cells. In 
response to type I IFNs, innate immune cells enhance antigen presentation and produce 
immune response intermediaries i.e., cytokines and chemokines. B cells produce 
antibodies and T cells effector function is amplified in response to type I IFNs as part 
of adaptive immunity (as shown in figure 8).  (Ivashkiv and Donlin, 2014). 
 
Fig 8: Type I interferon controlling innate as well as adaptive immune response along 
with antimicrobial programmes with in cell (Taken from Ivashkiv et al., 2014 
(Ivashkiv and Donlin, 2014)). 
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c. Mechanism of IFN Action 
IFN- α/ȕ receptor (IFNAR), expressed ubiquitously and constitutively, is a 
heterodimer consisting of two subunits namely R1 and R2. IFN- α/ȕ interaction with 
the receptor results in its dimerization and in turn activation of the JAKs which 
phospohorylate IFNAR1/2 cytolpasmic domains. STAT1 and STAT2 are recruited to 
the receptor, phosphorylated and then associate with interferon regulatory factor-9 
resulting in the formation of interferon-sensitive gene factor-3 (ISGF3). ISGF3 then 
translocates in the nucleus to regulate interferon-sensitive genes (ISGs) expression by 
transactivation of the interferon-sensitive response elements (ISRE) (Huber and Farrar, 
2011).  
 
Fig 9: Type I Interferon: Signal Transduction (Figure redrawn from (Taylor et al., 
2000)) 
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IFN-inducible genes and their subsequent proteins, that inhibit virus 
replication, include RNA-dependent protein kinase (PKR), β’,5’-oligoadenylate 
synthetase (OAS), Major histocompatability complex (MHC) and Mx proteins. PKR 
plays role by inhibiting translation initiation and β’,5’ OAS mediates degradation of 
RNA. IFN-α triggers MHC class I antigen expression in immune cells and activates 
effector cells besides interaction with cytokine cascade. IFN- α also performs immune-
modulatory functions by stimulating TH1 cells production whereas reducing the 
production of TH2 cells. The whole mechanism result in antiviral state within infected 
cells that directly inhibits viral replication at the same time it also enhances antiviral 
immune responses of the host (Vezali et al., 2011). The JAK-STAT pathway 
malfunctioning can lead to pathogenesis in some human diseases (Igaz et al., 2001). 
4. Molecular Mechanism responsible for Interferon Resistance 
To date IFN and ribavirin are the only successful HCV treatment regimen 
availabe. HCV evolved diverse mechanisms to evade IFN response through blocking 
downstream signaling i.e., STAT1, STAT2, IRF9 and JAK-STAT pathways and IFN 
Stimulatory Genes (ISGs) repertoire (Qashqari et al., 2013). According to a number of 
studies, host factors (demographic and genetic) and viral factors i.e., genetic 
heterogeneity affects IFN therapy outcome (Qashqari et al., 2013, Asselah et al., 
2010). Many studies demonstrated up-regulation of some ISGs in non-responders 
before treatment. Clinical, biochemical and histological findings can predict the 
therapy response before treatment starts. This is of great concern because standard 
treatment for HCV is physically as well as economically demanding. Different factors 
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are associated with IFN therapy failure i.e., viral factors, host factors and HCV 
induced molecular mechanisms that inhibit IFN signaling pathway. In order to 
determine treatment response, gene expression analysis has been done in liver 
biopsies. (Asselah et al., 2010). Among the liver genes, the decreased expression of 
IFN-α receptor might be the cause of resistance to therapy in HCV patients. 
Responders have shown higher levels of receptor mRNAs in liver compared to non-
responders (Ahmad et al., 2012). A study showed 97% of HCV patients expressing 
IFN-α mRNA whereas γ0% of HCV patients expressing IFN-α receptor mRNA and 
hence concluded that lower IFN-α receptor expression is associated partially with 
interferon resistance to therapy in these patients (Salama H, 2007). As the expression 
of IFNAR1 and IFNAR2 is key to success of IFN- α treatment in viral hepatitis hence 
the receptor expression downregulation could result in treatment failure. So treatment 
success depends largely on levels of IFN- α receptor expression and can be a predictor 
of response to therapy. Fibrotic livers also have downregulated expression of the IFN- 
α receptor (Gao et al., 2004). IFN-resistant phenotypes (partially IFN resistant & 
highly IFN resistant) possessing HCV replicon-harbouring cell lines when used to 
evaluate viral and cellular factors responsible for IFN resistance, results showed that 
cellular factors contributed to IFN-resistance including observation that genetic 
abnormality in IFN-α receptor also resulted in interferon resistance (Naka et al., 
2005a).  
Identifying the factors responsible for non-responsiveness can be helpful in 
predicting the treatment response. Resistance to therapy can be result of different 
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factors including viral factors, host factors and HCV proteins induced molecular 
mechanism that inhibits IFN signaling cascade (Asselah et al., 2010). It has been 
observed that cellular factors as compared to viral factors contribute to a phenotype 
that is highly resistant to IFN (Naka et al., 2005b). Though the world has progressed in 
different aspects to figure out the main defects associated with the interferon resistance 
in HCV patients, in Pakistan, the role of interferon receptors in HCV patients resistant 
to therapy has not been investigated. Neither the molecular nor immunological level 
studies have taken into consideration to figure out this pivotal/ critical issue in 
Pakistan. So keeping in view the importance of the cellular factors, a study was 
designed based on analyzing cellular factors that are thought to be key to success for 
the therapy i.e., Interferon alpha receptor. The current study was aimed to investigate 
the qualitative expression analysis of IFN-α receptor among HCV infected patients 
resistant to standard interferon therapy and disease severity. Along with this, the risk 
factors exposed to subjects included in the study along with their awareness level 
regarding HCV was also evaluated.  
5. Risk Factors and Socioeconomic Status of HCV Infected Patients 
Risk factors regarding HCV infection vary significantly among countries and 
geographic regions (Karaca et al., 2006). Pakistan is one of the nations that are worst 
affected by HCV and mortality as result of liver failure and HCC. Taking into 
consideration the size of Pakistan and its large growing population, there are no 
estimates available at national level regarding prevalence of hepatitis and associated 
risk factors. Much is known about risk factors as evident from the published literature 
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in Pakistan (Ali et al., 2009). We also identified the possible risk factors among the 
population that we selected for this research.  
Hepatitis C causes many extrahepatic manifestations ultimately resulting in 
poor health-related quality of life (HRQOL). There are many other factors behind poor 
quality of life in HCV patients including physical as well as psychological factors 
(Abdo, 2008) including change in behavior, internalized shame, financial insecurity 
and social rejection (Zacks et al., 2006).  
Socioeconomic status (SES) is the position of a person in a society and can be 
estimated by criteria like education, job/occupation and income. Studies from USA, 
Norway, France and Puerto Rico are evident for associations between HCV prevalence 
and different markers of SES. An increase in risk of acquiring HCV infection has been 
observed in people with low SES (Omland et al., 2013). The current study also aimed 
to investigate the possible involvement of SES as risk factor for HCV infection. 
6. Basic HCV Awareness  
Many persons are not aware of HCV infection because of asymptomatic and 
hence they do not undergo for HCV screening unless they develop complications of 
liver and then seek for medical care which is also a small portion of people among the 
infected patients who are unaware that they have acquired HCV infection (Denniston 
et al., 2012).  Hence awareness is very important to manage and treat HCV. Recent 
studies show that awareness level regarding HCV is extremely low among general 
Pakistani population especially among women and people who are less educated 
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(Jamil et al., 2010, Asif et al., 2009). Healthcare workers are at higher risk of HCV 
infection. Studies have shown that most of the sharps injuries were sustained while 
drawing blood or injecting practices. Wearing gloves can help avoid infection 
contraction. Medical students are at higher risk of acquiring infections as they deal 
patients, have direct contact with them and with blood (transfusions) and surgical 
instruments/injections. There is a need to start training regarding infectious diseases 
precautions in countries lacking safety equipment, safety instructions for infectious 
diseases and staff vaccination programmes (Anjum et al., 2005). Most of HCV/ HIV 
patients visit hospital daily for consultations, admissions, procedures and diagnosis 
and hence encounter health care workers. Medical students (also included in healthcare 
delivery system) are at high risk as they also deal with patients and infected 
instruments (Saleem et al., 2010). Usually the medical students are associated with the 
activities related to care of the patient and are first level of contacts with the patients in 
start of their clinical years. Being future doctors, at the start of the clinical rotations, 
they are at high risk of infections because of lack of experience and skill. At this stage 
they must have sound knowledge of the blood borne diseases like HCV infection as 
medical student’s awareness for HCV is very important not only for their own safety 
but also for the effective patient care with whom they are in direct contact. 
Misconceptions regarding basic knowledge for HCV may put them at higher risk as 
well as can hinder the effective interaction between patient and doctor. Lack of 
knowledge regarding actual routes of HCV transmission can put the student at high 
risk of getting HCV infection and on the other side, misconception regarding HCV 
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transmission route can hinder the student to keep in close contact with the patient, take 
care of the subject and his/her better treatment.  
Objective of the Study: 
o The main objective of the study was to analyze the expression of 
IFNAR1, IFNAR2 and STAT1 in HCV infected patients resistant to 
standard interferon therapy by qualitative PCR analysis and their 
relation with clinical investigations e.g., liver function tests, viral load, 
liver histopathology i.e., disease severity in Pakistani subjects.  
o The second main objective of the study was to estimate the basic 
awareness level about HCV transmission routes and risk factors among 
normal healthy subjects, subjects with history of HCV infection and 
medical students who are at the start of their clinical rotation.    
o The third main objective was to find out the major risk factors exposed 
to subjects included in the study and evaluation of socioeconomic status 
of hepatitis C infected patients as a possible risk factor keeping in view 
the high cost of HCV diagnosis and treatment (economic burden on 
common person and HCV burden in the country). 
 
 
 
 
26 
 
Chapter 2 
MATERIALS AND METHODOLOGY 
2.1   ETHICAL COMMITTEE APPROVAL 
The study was conducted after formal approval was obtained from the Ethics 
Committee, Army Medical College, Rawalpindi. Informed written consent was 
obtained from all the subjects enrolled in the study. Those who refused to take part in 
the study were not included in the final data analysis. 
2.2    STUDY DESIGN 
The study consisted of qualitative as well as quantitative methodologies to 
understand the reasons why HCV risk and prevalence in our population is getting 
higher day by day and why this virus is not responding to interferon treatment.  
Defining the sample population for qualitative research 
 For qualitative research we conducted comprised structured, self-administered 
questionnaire based cross sectional study that included the following groups: 
1. Subjects having HCV infection history including responders (N=15) as well as 
non-responders to interferon therapy (N=50) 
2. Normal healthy subjects (N=15). One lady didn’t participate in the study so she 
was not included in the final data analysis.  
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3. For awareness survey, 179 medical students were also included in the studies 
that are at the start of clinical rotation. 
The subjects included in the study were selected based on convenience 
sampling method. 
The subjects included in the qualitative research were assessed for  
1. Awareness regarding routes of HCV transmission  
2. Risk factor exposure during their life time that can be possible sources of 
acquiring HCV infection. 
3. Socioeconomic status (SES) of the subjects included in the study. Because 
SES is thought to be an emerging and most dangerous risk factor for HCV 
transmission. 
4. The total cost of HCV diagnosis and treatment was also estimated to 
explain the reason why people are not getting timely diagnosis and follow 
complete treatment plan for this asymptomatic disease. This is one of the 
very important reasons for high burden on the finance of the common man 
and high prevalence of HCV in Pakistan.  
Defining the sample population for quantitative research 
 For quantitative research, the main focus was on HCV infected patients 
resistant to standard interferon therapy included in the study based on convenience 
sampling method. The following groups were also included in the group along with the 
above mentioned group: 
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Group I: A control group of normal healthy individuals (n=15) both males and 
females i.e., those negative for HCV, other viral hepatitis and HIV. 
Group II: Second control group comprised of individuals (n=15) both males 
and females that were previously infected with HCV but responded to standard 
interferon treatment (i.e., they received subcutaneous injections of recombinant IFN-α 
with 3 million IU dose thrice weekly and ribavirin with 10 mg/ kg body weight/ day 
with 24 weeks therapy duration) and were negative for serum HCV RNA, other viral 
hepatitis and HIV. 
Group III: Individuals infected with HCV that didn’t respond to twice course 
of standard interferon treatment (n=50). Both male and female patients were included 
in the study. The other inclusion criteria were patients positive for anti-HCV 
antibodies and serum HCV RNA with or without elevated ALT levels. HCV genotype 
3 patients were included in the study. The exclusion criteria for the study were HCV 
patients co-infected with other viral hepatitis or HIV, abnormal bleeding time, platelet 
count and prothrombin time. 
The subjects included in the quantitative research were assessed for  
1. Demographic features 
2. Body mass index 
3. Blood tests 
a. Pre-biopsy tests 
i. Bleeding time 
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ii. Clotting time 
iii. Prothrombin time (PT)/Partial thormboplastin time with 
kaolin (PTTK) 
The patients normal for pre-biopsy tests were then undergone 
for liver biopsy.  
b. Liver function tests 
i. Alanine Aminotransferase (ALT) estimation 
ii. Alkaline Phosphatase (ALP) estimation 
iii. Bilirubin estimation 
c. ELISA based screening of viral hepatitis and HIV/ AIDS 
d. Viral load estimation 
e. HCV genotyping (HCV genotype 3 infected patients were included 
in the study) 
4. Abdominal ultrasound 
5. Liver biopsy and histopathology 
6. PCR based expression detection  
a. IFNAR1 
b. IFNAR2  
c. STAT1 
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2.3   QUESTIONNAIRE 
The questionnaire (Appendix I) was designed and assessed for its validity by a 
panel of clinical experts. The questionnaire had four parts. First part was for 
demographic data comprising of participant’s age, gender and marital state. Second 
part was focused on knowledge of risk factors associated with HCV infection and 
comprised of questions to evaluate the knowledge level of the participants about routes 
of HCV infection and risk factors associated. Third part was to evaluate socio-
economic status focusing on three markers i.e., education, employment/occupation and 
income. Forth part was focused on probable exposure to risk factors that can be 
important for acquiring HCV comprising detailed interview of the patients. The 
participants of the study were briefed about the purpose of the study and assured about 
the data confidentiality. Filling a questionnaire took around 20 minutes by each 
participant. The data was coded and then analyzed using SPSS for Windows version 
20.0. Awareness questionnaire was adopted from (Mayor et al., 2010) and (Tiftikci et 
al., 2009) with some modifications, the questionnaire is attached as annexure.. Risk 
factors exposure questionnaire was adopted from the articles by Ghias (Ghias and 
Pervaiz, 2009, Ghias et al., 2010) with some modifications. Three markers of 
socioeconomic status as mentioned by Omland (Omland et al., 2013) were also 
determined. We also approximately estimated the cost of diagnostic tests and treatment 
for HCV in Pakistan. 
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2.4  SAMPLE COLLECTION 
Blood as well as biopsy samples were taken from HCV infected patients 
resistant and responder to standard interferon therapy reporting to the department of 
medicine, Military Hospital, Rawalpindi. Biopsy samples were not available for 
normal healthy individuals and previously HCV infected subjects who responded to 
IFN treatment hence the blood was used for further analysis. Blood was processed the 
same day for RNA extraction and liver biopsies were stored at -80°C for further 
processing.  
A. Blood Sample Collection 
Blood samples were collected from all participants of the quantitative research 
under fully aseptic conditions. All specimen tubes were marked with the identification 
of the patient. Blood was drawn from the median cubital vein. The tourniquet was 
placed on the upper part of the arm (3 to 4 inches above the venipuncture site), tight 
enough to make the vein bulge. The sample was collected in the specimen tubes which 
were properly labeled with patient’s particulars. The needle was disposed off by using 
the cutters. The samples were then transported in liquid nitrogen from MH (Military 
Hospital, Rawalpindi)/ CMH (Combined Military Hospital, Rawalpindi) to CREAM 
(Center for Research in Experimental & Applied Medicine), department of 
Biochemistry, Army Medical College, Rawalpindi. The sample was processed for 
RNA extraction the same day it was collected. 
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B. Ultrasound Guided Liver Biopsy 
Ultrasound guided liver biopsy was performed to obtain liver sample from the 
patients. Before arriving for biopsy, patients were asked not to take blood thinners, 
aspirin/ aspirin-related medications for 7 days before biopsy, not to eat/ drink for 8 
hours before biopsy and to take prescribed medications with a little amount of water. 
Some blood tests were performed before liver biopsy i.e., bleeding time, platelet count, 
prothrombin time (PT). After arriving for biopsy, brief clinical assessment was done 
i.e., pulse and blood pressure were measured. Biopsy procedure was explained to the 
patient. Risks and benefits of biopsy were explained and informed written consent was 
taken on a consent form indicating willingness of the patient to undergo biopsy 
procedure and participate in the study. During biopsy, the patient’s ultrasound images 
of abdomen were obtained in order to locate biopsy area precisely. After locating the 
liver biopsy area, the abdomen was cleaned and sterilized/ disinfected. Sterile gloves 
were used for the biopsy procedure. For biopsy, special needle device was inserted 3 
cm and liver sample was removed. A staple gun like noise was heard marking that 
sample is taken. After biopsy, patient was observed for four hours to monitor any 
complications associated with liver biopsy. The patient suffered some pain but he/ she 
was given the painkiller medications for his/her comfort.  
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Transportation of specimens 
Transportation of the biopsy sample was carried out under strict aseptic 
conditions. Hands were washed and sanitized before and after sample collection. 
Samples were placed aseptically in sterile containers. The container was closed tightly 
during transportation in order to avoid any leakage. The container was labeled and date 
marked. The specimens were immediately transported to the laboratory for storage 
after biopsy. 
2.5  CLINICAL PARAMTERS  
Patients were monitored using following parameters; body mass index  (BMI), 
pre-biopsy tests (Bleeding time, Platelet count, Prothrombin time), histopathological 
state of the liver (H & E staining), viral load by quantitative PCR, genotype of the 
HCV, LFTs (ALT, ALP, Bilirubin) and screening for all viral hepatitis.  
A. BODY MASS INDEX (BMI) 
BMI was calculated using the English system. The BMI was measured by first 
taking the weight of the patient in pounds (lbs) and height in inches.  
Using English system, the BMI formula is as follows: 
Weight (pounds: lbs) divided by height (inches (in)) squared and multiplied by 703 
(conversion factor to express BMI in SI units i.e., kg/m2).   
BMI=   Weight (lbs) x 703 
                                                               Height (in)2 
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Results interpretation: 
For adults i.e., people aged 20 years old and above, the BMI results can be 
interpreted using the categories of standard weight status (that are same for male and 
female of all ages). The standard weight status categories and respective BMI values 
(adults) are as follows: 
BMI Weight status 
Below 18.5 Underweight 
18.5 to 24.9 Normal 
25.0 to 29.9 Overweight 
30.0 and above Obese 
 
B. PRE-BIOPSY TESTS 
a. Bleeding Time: 
Bleeding time was measured using the Ivy’s method.  
Requirements: 
 Sphygmomanometer 
 Lancet 
 Circular filter paper 
 Stop watch 
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Procedure: 
1. The sphygmomanometer cuff was applied to the patient’s arm who was lying 
supine on a couch. 
2. The cuff was inflated to 40mm Hg which was maintained during the test. 
3. Forearm volar surface was cleaned with spirit swab and area was chosen 
without any visible veins. 
4. Two cuts 4-8mm long and 1 mm deep separate punctures 5-10cm apart were 
made along the long axis of the forearm using standard depth lancet. 
5. The blood was allowed to flow out freely and stop watch was started. 
6. The oozing blood was blotted using the edge of the filter paper (circular) by 
gentle touch after every 15 sec. The blood was keep on blotting until the blood 
flow stopped and no more blood spot was seen on blotting paper.  
7. The stop watch was stopped and time was noted. This was the bleeding time. 
References values: Ivy’s method using lancetμ β-7 minutes  
b. CLOTTING TIME: 
 Disposable syringes  
 Glass test tubes (75x12mm with 10mm bore) 
 Water bath for incubation at 37ºC 
 Stop watches: 3 
Procedure: 
1. Three glass test tubes were placed in water bath maintained at temperature 
37ºC. 
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2. The vein puncture site was cleaned with spirit swab and allowed to dry. 
3. Then 3mL of blood was collected using sterile disposable syringe. The all of 
the three stop watches were started as the blood entered the syringe. 
4. Then 1mL blood was put in each of 3 glass test tubes placed at 37ºC in water 
bath. 
5. To see the blood clotting, the tubes were tilted initially after 4 min and then 
every 30 sec. 
6. The stop watch was stopped for the tube in which blood clotted. Time was 
noted for each tube. Mean was taken for three readings. That was the clotting 
time. 
Reference values: 5-11 minutes  
c. PROTHROMBIN TIME (PT) 
Requirement: 
 Patient’s platelet poor plasmaμ λμ1 ratio of patient blood and trisodium citrate 
(31.3g/L trisodium dihydrate) was added in plastic tube. Centrifugation was 
done at 2,000xg for 15 min at 4ºC. The platelet poor supernatant plasma was 
collected into a plastic tube for testing. 
 Normal control plasma: Preparation was done by pooling platelet poor plasma 
from 4-20 normal healthy subjects. 
 Thromboplastin: Commercially available Thromboplastin was used. 
 Glass tubes (75x12mm) 
 Automatic pipettes (100) 
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 Water bath 
 Stop watches 
 Table lamp 
Procedure:  
1. The table lamp was set on water bath the way that tubes were seen against it 
but eyes were safe from direct light. 
2. Four plain glass tubes were placed in water bath set at 37ºC. 
3. Then 100µL test plasma was delivered in a test tube and then wait for 2 min. 
4. Then 200µL tissue thromboplastin (commercially available) was delivered and 
the stop watch was started. The contents were mixed and left for 6-8 sec. 
5. The tube was examined after 6-8 sec against light shield by tilting to see any 
clot formation and then after every 1-2 sec by taking the tube briefly out of 
water. 
6. The stop watch was stopped as the visible clot formation occurred in the test 
tube and time was noted. 
7. The procedure was repeated on test plasma. Then the mean of these two 
recorded times was taken. 
8. The test was then repeated using control plasma. 
Reference values:  10-14 sec 
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d. PARTIAL THORMBOPLASTIN TIME WITH KAOLIN (PTTK) 
Requirements: 
 Test and control plasma were prepared as for prothrombin time. 
 Platelet substitute used was commercially available. 
 Kaolin in barbitone buffer (Ph 7.4) 
Sodium diethylbarbiturate  11.74g 
Hydrochloric acid   430mL 
Kaolin     2.15g 
 Calcium chloride 
 Automatic pipettes (100µL and 200µL volume) 
 Test tubes (plastic and glass) 75x12mm 
 Stop watches 
 Timer 
 Table lamp 
 Water bath 
Procedure: 
1. Equal volume of platelet substitute and kaolin suspension were mixed and left 
in water bath (to warm). 
2. The 75x12mm glass tube was placed in water bath. 
3. Then 100µL test plasma was delivered in pre-warmed test tube. 
4. Then 200µL platelet substitute-kaolin mixture was added to it. The timer was 
started. Mixing was done at intervals. 
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5. Incubated for 10 minutes in water bath. 
6. Then 100µL calcium chloride was added and stop watch was started. The clot 
formation was observed at intervals as in prothrombin time estimation 
procedure. The stop watch was stopped as soon as the fibrin clot appeared. 
Time was noted. 
7. The procedure was repeated on test plasma. Then the mean of these two 
recorded times was taken. 
9. The test was then repeated using normal pooled plasma. 
Reference values:  25-43 sec 
 
C. HISTOPATHOLOGICAL STATE OF THE LIVER (H & E STAINING) 
The liver biopsy specimens were fixed in 10% formalin and then embedded in 
paraffin. Dehydration of the specimen was done by incubating the specimens in 80% 
alcohol for one hour, 95% alcohol for one hour, 100% Alcohol for one hour and then 
with a second incubation with fresh 100% Alcohol for one hour. The specimen was 
cleared by incubating in xylene for two hours and the step was repeated with fresh 
xylene. Infiltration was done using paraffin with TM (melting temperature) 56-58 °C 
for two hours and the step was repeated once. Filtered paraffin with TM (melting 
temperature) 56-58 °C was used for the process of embedding. Metallic molds were 
used to prepare blocks. Molten paraffin wax was filled in each mold and tissue was 
carefully placed in the Center of mold. Mold was then allowed to cool at room 
temperature and then shifted to refrigerator. Sectioning was done by placing the block 
in block holder of rotary microtome. And sections of 4-5 um thickness were made and 
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floated in water bath at temperature 45 °C and taken separately on two different slides 
coated with albumin. Creases were removed by clipping the slides horizontally in 70 
% alcohol bath. For about 30 minutes, slides were kept in slanting position draining 
excessive water. Sections were dried on hot plate for ~15–30 minutes at 60 °C. 
Staining was done using H & E stain which was used for first slide. To demonstrate 
fibrosis, reticulin stain was used for second slide. Stained sections were mounted using 
canada balsam and covered with cover slip. Knodell’s scoring system was used to 
evaluate the extent of liver damage.  
D. LIVER FUNCTION TESTS: 
i. ALT Estimation:  
ALT estimation was done using Liquick Cor-ALAT (Cormay, Poland) kit 
method (cat# 1-312). Serum was separated from the blood sample. Working reagent 
(1000µl) was prepared by mixing gently 4 parts of 1-ALAT and 1 part of 2-ALAT 
avoiding foam formation. Working reagent (1000µl) was pipette into the cuvette and 
brought up to the temperature of determination (25 ºC). Then 100µl of sample was 
added to the cuvette, mixed and then incubated for 1 minute at 25  ºC temperature. 
Absorbance at 340nm was taken against water. The readings were repeated exactly 
after 1, 2 and γ minutes. Change in mean absorbance per minute (ΔA/min) was 
calculated.  
ALAT activity [U/l]= ΔA/min. Χ F  (F value=1746 at 340nm) 
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Reference values (25ºC): Serum/ Plasma of women (up to 42 U/l) and men (up 
to 36 U/l) 
ii. ALP Estimation: 
ALP estimation was done using Liquick Cor-ALP (Cormay, Poland) kit method (cat# 
1-317). Serum was separated from the blood sample. Working reagent (1000µl) was 
prepared by mixing gently 4 parts of 1-ALP and 1 part of 2-ALP avoiding foam 
formation. Working reagent (1000µl) was pipette into the cuvette and brought up to 
the temperature of determination (γ7  ͦ C). Then β0µl of sample was added to the 
cuvette, mixed and then incubated for 1 minute at γ7  ͦ C temperature. Absorbance at 
405nm was taken against water. The readings were repeated exactly after 1, 2 and 3 
minutes. Change in mean absorbance per minute (ΔA/min) was calculated.  
ALP activity [U/l]= ΔA/min. Χ F    (F value=2764 at 405nm) 
Reference values: Serum/ Plasma levels  (132-365 U/l) 
iii. Bilirubin Estimation 
Bilirubin estimation was done using Linear Chemicals S. L Spain kit method 
(Ref# 1111025). Serum was separated from the blood sample. Working reagent was 
prepared by mixing gently 1 part of RN and 4 parts of RT. Three tubes were taken and 
labelled reagent blank, sample blank and sample. Reagent blank contained 100 µL of 
water, sample blank contained 100 µL sample and 1.0mL RT solution, Sample 
contained 100 µL Sample and 1.0 mL of working reagent. The tubes were mixed 
thoroughly allowed to stand for 2 minutes at room temperature. Absorbance of sample 
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blank was taken at 540nm against water and absorbance of sample was taken at 540nm 
against reagent blank. 
Calculations were done using the formula: 
A(Sample)-A(Sample blank) ΧC(CSal)   = mg/dL total bilirubin 
        A(Cal) 
Reference values: Serum/ Plasma of Adults (up to 1.0mg/dL)  
E. VIRAL RNA PURIFICATION  
Viral RNA purification was carried out using QuickSpin ® Viral Nucleic Acid 
Purification kit (Aj Roboscreen, Germany, CAT# NAP-01-03-050).  
Reagent preparation: 
Lysis buffer and wash buffer 2 were prepared before proceeding for viral RNA 
purification protocol. Lysis buffer was prepared by adding the carrier RNA contents to 
the whole lysis buffer bottle. Wash buffer 2 was prepared by adding 50mL ethanol to 
the whole bottle of concentrated wash buffer 2. 
Protocol: 
a) Virus Lysis 
 A 600 µL volume of lysis buffer (carrier RNA added) was added to 150 µL 
serum sample. Mixing was done by pipetting up and down and vortexing well. 
Incubation was done at 70ºC for 5 min.  
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b) Adjusting Binding Conditions 
 Then 600 µL volume of ethanol (absolute) was added to the clear lysis 
solution. Mixing was done by vortexing for 10-15 sec. 
c) Binding Viral RNA 
 Binding columns were placed in 2ml collection tubes and 700 µL of lysed 
sample was loaded on it. Centrifugation was done at 8,000 x g for 1 min. The residual 
lysis solution was again reloaded on to the binding column. Centrifugation was done at 
8,000 x g for 1 min. The flow-through was discarded. The binding column was placed 
into new 2 ml collection tube.  
d)  Washing and Drying Silica Membrane: 
i. 1st Washing 
First washing was done by adding 500 µL wash buffer 1 on to the 
column.  Centrifugation was done at 8,000 x g for 1 min. The flow-
through was discarded. 
ii. 2nd Washing 
Second washing was done by adding 600 µL wash buffer 2 on to the 
column. Centrifugation was done at 8,000 x g for 1 min. The flow-
through was discarded. 
iii. 3rd Washing 
Third washing was done by putting the spin column in new 2ml 
collection tube and adding 200 µL wash buffer 2 on to the column. 
Centrifugation was done at 11,000 x g for 5 min to completely remove 
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wash buffer 2 supplemented with ethanol. The flow-through was 
discarded. 
e) Viral Nucleic Acid Elution 
 The spin column was then placed into a new 1.5ml sterile microcentrifuge tube. 
Then 50 µl 70ºC preheated RNAase-free water was added to the column and incubated 
for 2 min. Centrifugation was done at 11,000 x g for 1 min. 
F. GENOTYPE OF THE HCV  
a) AMPLICOR® HCV Test, v2.0: Reagent Preparation 
1. The number of reactions tubes required were taken including for 
specimen as well as control. The reaction tubes were placed in 
MicroAmp tray and locked in place with the help of retainer.  
2. Working master mix was prepared by adding 100µl HCV Mn2+, v2.0 
to single vial of HCV MMX,v2.0. Then 100 µL HCV Mn2+, v2.0 was 
added to HCV MMX, v2.0 entire vial. The tubes were recaped and 
mixed thoroughly by inverting 10-15 times. The remaining HCV 
Mn2+,v2.0 was discarded. Working master mix was stored at 2-8ºC and 
used subsequently with in 4 hours of preparation. 
3. Then 50 µL of working master mix was added in each reaction tube. 
4. The tray containing working master mix and capped reaction tubes 
were placed in a resealable plastic bag. The bag was sealed securely.  
b) AMPLICOR® HCV Test, v2.0: Specimen and Control Preparation for  
1. The 70% ethanol (15mL) was prepared that was enough for 12 tests. 
2.  The tubes were labeled for specimens, HCV(-)C and HCV(+)C.  
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3. Working lysis reagent was prepared by vortexing HCV IC, v2.0 for 10-
15 sec. For each batch i.e., 12 specimens and controls, 100 µL HCV IC, 
v2.0 was added to the single bottle oh HCV LYS, v2.0 and mixed well.   
4. Then 400 µL of working lysis reagent was added to each of the labeled 
tubes and the tubes were capped.  
5. Controls were prepared as follows 
i. NHP, HCV(-)C,v2.0 and HCV(+)C, v2.0 were vortexed for 5-10 
sec. 
ii. Then 200 µL NHP was added to both of the control tubes. 
Tubes were capped and vortexed for 3-5sec. 
iii. Then 20 µL of HCV(-)C,v2.0 was added to the tube having 
“HCV(-)C” label containing working lysis reagent and NHP. 
Tubes were capped and vortexed for 3-5sec. 
iv. Then 20 µL of HCV(+)C,v2.0 was added to the tube having 
“HCV(+)C” label containing working lysis reagent and NHP. 
Tubes were capped and vortexed for 3-5sec. 
6. A 200 µL of each specimen was added to their respective labeled tubes 
containing working lysis buffer. Tubes were capped and vortexed for 3-
5sec. 
7. The sample and control tubes were incubated at about 60 ºC for 10 min. 
The tubes were then vortexed for at least 10 sec. 
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8. The caps were removed from the tubes, 600 µL isopropanol (100%, 
room temperature) was added to each tube. Tubes were recapped, 
vortexed for 3-5 sec and incubated for 2 min at room temperature. 
9. Orientation of each tube was marked and placed in microcentrifuge 
with orientation mark facing outwards. The pellet formed will align 
orientation mark. Centrifugation was done for 15 min at 12,500-
16,000xg at room temperature. 
10. Supernatant was discarded.  
11.  Then 1.0mL 70% ethanol was added to each tube. The tubes were 
recapped and vortexed for 3-5sec. 
12. The tubes were again centrifuged for 5 minutes with the same 
procedure as mentioned in step 9. 
13. Supernatant was discarded. 
14. The tubes were recapped and centrifuged for 3-5sec at maximum 
speed.the supernatant was removed carefully. 
15. Then 200 µL HCV DIL, v2.0 was added to each tube. Pellet was 
dissolved using pipette and vigorous vortexing for 10 sec. the processed 
tubes were subjected to amplification with in 3 hours preparation.  
16. A 50 µL of sample (specimen as well as control) were added to each 
reaction tube that contains working master mix. Reaction tubes were 
capped and sealed using MicroAmp Cap Installing Tool. 
17. The position of each tube was recorded 
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c) AMPLICOR® HCV Test, v2.0: Reverse Transcription and Amplification 
1. The tray was placed in thermal cycler block. 
2. GeneAmp PCR System 2400 was programmed as follows: 
Program Temp Time 
HOLD Program 50 ºC 5min 
HOLD Program 62 ºC 30 min 
CYCLE Program 90 ºC 10 sec 
58 ºC 25 sec 
HOLD Program 91 ºC Not to exceed 3 hours 
  
3. The tray was removed thermal cycler during the final HOLD program.  
4. The caps were removed from the reaction tubes, 100µL [1] DN was 
added to the reaction tubes and mixed by pipetting up and down. 
Incubation was done at room temperature for 10 min to allow 
denaturation completely. 
5.  The reaction tubes were then saved at room temperature to process 
with in 2 hours for AMPLICOR® HCV Test, v2.0 detection.  
d) AMPLICOR® HCV Test, v2.0: Detection 
1. All reagents were warmed to room temperature 
2. Water bath was warmed at 50ºC  
3. Working hybridization buffer was prepared as follows: 62.5mL SSPE 
was added to 432.5mL distilled water and mixed well. Then 5mL SDS 
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was added and mixed well. Working hybridization buffer was stored at 
room temperature. 
4. Working stringent wash buffer was prepared as follows: 25mL SSPE 
was added to 965mL distilled water and mixed well. Then 10mL SDS 
was added and mixed well. Working stringent wash buffer was stored at 
room temperature. 
5. Working ambient wash buffer was prepared as follows: 37.5mL SSPE 
was added to1447.5mL distilled water and mixed well. Then 15mL 
SDS was added and mixed well. Working ambient wash buffer was 
stored at room temperature. 
6. Working citrate buffer was prepared as follows: 50mL CIT was added 
to450mL distilled water and mixed well. Working citrate buffer was 
stored at room temperature. 
7. Working hybridization buffer and working stringent wash buffer were 
warmed to 50ºC.  
8. Shaking water bath was pre-warmed at 55ºC and set at 60 rpm shaking 
speed.  
9. HCV strips were taken using clean forceps. 
10. HCV strips were labeled using water proof ink pen 
11. Strips were placed in the wells of 24 well tray with probe lines facing 
upward 
12. Then 4mL working hybridization buffer was added to each well 
containing labeled strip. 
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13. Then 100µL denatured amplicon was added to each well containing 
labeled strip. The tray was rocked gently between each addition. 
14.  The tray was covered with lid placed in 55ºC and allowed to hybridize 
for 20 min at 60 rpm shaking. 
15. Working conjugate was prepared as follows: 10µL SA-HRP was added 
to 5mL pre-warmed stringent wash buffer for each strip tested.  
16. The tray was removed from shaking water bath. Working hybridization 
buffer was removed. 
17. Then 4mL of working ambient wash buffer was added to each well of 
typing tray. Typing tray was gently rocked 3-4 times to rinse strips and 
working ambient wash buffer was removed. 
18. Then 4mL working conjugate was added to each well of the typing tray. 
The typing tray was covered with lid and incubated back to water bath 
at 55ºC and 60 rpm shaking speed for 20 min. 
19. The tray was removed from shaking water bath. Working conjugate was 
removed. 
20. Then 4mL of working ambient wash buffer was added to each well of 
typing tray. Typing tray was gently rocked 3-4 times to rinse strips and 
working ambient wash buffer was removed. 
21. Then 4mL of working stringent wash buffer was added to each well of 
typing tray. The typing tray was covered with lid and incubated back to 
water bath at 55ºC and 60 rpm shaking speed for 12 min. 
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22. The tray was removed from shaking water bath. Working stringent 
wash buffer was removed. 
23. Then 4mL of working ambient wash buffer was added to each well of 
typing tray. Tray was incubated at room temperature orbital shaker, 60 
rpm shaking speed for 5 min. 
24. The tray was removed from orbital shaker. Working ambient wash 
buffer was removed. 
25. Then 4mL of working citrate buffer was added to each well of typing 
tray. Tray was incubated at room temperature orbital shaker, 60 rpm 
shaking speed for 5 min. 
26. Working substrate was prepared as follows: 4mL of SUB A was added 
to 1mL SUB B (per strip to be tested) and mixed well and stored at 
room temperature. 
27. The tray was removed from orbital shaker. Working citrate buffer was 
removed. 
28. Then 4mL of working substrate was added to each well of typing tray. 
Tray was incubated at room temperature orbital shaker, 60 rpm shaking 
speed for 10 min. 
29. The tray was removed from orbital shaker. Working substrate was 
removed. 
30. Then 4mL of distilled water was added to each well of typing tray. Tray 
was incubated at room temperature orbital shaker, 60 rpm shaking 
speed for 5 min. 
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31. The tray was removed from orbital shaker. Distilled water was 
removed. 
32. Then 4mL of distilled water was added to each well of typing tray. Tray 
was incubated at room temperature orbital shaker, 60 rpm shaking 
speed for 5 min. 
33. The tray was removed from orbital shaker. Distilled water was 
removed. 
34. Then 4ml of distilled water was added to each well of typing tray. 
Strips were stored (for up to single day) in water at room temperature 
until interpretation. 
G. VIRAL LOAD 
HCV Viral load was estimated using RoboGene® HCV RNA Quantification Kit 
(Aj Roboscreen, Germany (Cat # 0207200162)). All the RT-PCR procedure was 
conducted at ice.  
Preparation of 25x reagent mix (25x HCV_D4) 
 A 40µL volume of PCR grade water was added to lyophilized HCV_D4 
reagent mix vial and the lid was closed. The vial was incubated for 20 min at 
37ºC. Vortexing was done for 3 sec and centrifugation was done at full speed 
for 5 sec.  
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REAGENT VOLUME (µL)/ 
REACTION 
FINAL CONCENTRATION 
PCR grade water 3.5  
2x Reaction mixture 12.5 1x, 3mM Mg-sulphate 
Mg-sulphate solution, 
50mM 
2.0 
 
4.0mM 
 results in final concentration 7.0mM of Mg-sulphate 
25x  HCV_D4  1.0 1x 
RT-PCR Enzyme Mix 1.0 1x 
 
 Vortexing was done for 3 sec to mix. Centrifugation was done at full speed for 
5 sec. 
 The sample tubes (HCV_D2_LP) and quatification standard (HCV_D3_LP) 
were identified carefully and placed onto rack. 
 Then 20 µL master mix (1x) was added to sample tubes as well as the 
quantification standard tubes. 
 Then 5.0µL PCR grade water was added to sample tubes and quantification 
standard tubes making the volume not exceeding final reaction volume 25µL. 
 5.0 µL of isolated RNA was added to the samples tubes respectively making 
the volume not exceeding final reaction volume 25µL. 
 The tubes were covered with caps. The sample and quantification standard 
strips were covered carefully. 
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 Centrifugation was done for 1 min at 200x g. 
 The strips were carefully placed into the real time instrument block. The wells 
were selected that contained standards, non-template controls and samples. The 
text was entered identifying sample/ standard and  number to represent quantity 
of standard. 
 The setup was run as follows: 
CLYCLING CONDITIONS FOR HCV RNA QUANTIFICATION 
Step  Temperature Time Repeat 
Reverse transcription 55 ºC 30 min 1 
Taq Activation 95 ºC 2 min 1 
Melting 95 ºC 30 sec  
45 Stem formation, fluorescence 
detection (FAM; JOE/VIC) 
45 ºC 30 sec 
Annealing/ synthesis 57 ºC 1 min 
Run time: ~2.5 hours 
Data Analysis: 
HCV RNA was estimated on the basis of C T values for HCV RNA sample and 
standard curve resulting from quantification standards analysis and assay specific 
calibration co-efficient. HCV RNA concentration was expressed in IU/mL.
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H. VIRAL HEPATITIS TESTS: 
a. HAV ELISA Based Detection 
Reagents Preparation: All components of IgM antibody to Hepatitis A virus ELISA 
kit were brought to room temperature (18-γ0◦C) before use. Reagents were shaken 
gently. Wash buffer was checked for any crystals, if found, were resolubilized by 
warming at γ7 ◦C. The stock wash buffer was diluted with 1μβ0 ration with distilled/ 
deionized water.  
Diluting the Sample: The specimen was diluted with 1:1000 ratio using normal 
saline. 
Adding Sample: The 100 µl sample, positive and negative controls were added to 
each well.  
Incubating the sample: The plate was covered with plate cover and incubated at 37 
◦C temperature for β0 minutes 
Washing:  After incubation, the plate cover was discarded and each well was washed 
5 times with diluted wash buffer. The microwells were soaked for 30-60 seconds each 
time. After final washing step, the plate was turned down onto blotting paper and 
tapped to remove any residual liquid. 
Adding Conjugate: A 100 µl OF HRP conjugate reagent was added to each well  
HRP Conjugate Incubation: The plate was then covered with plate cover and incubated 
at temperature γ7 ◦C for 40 minutes. 
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Washing: The plate cover was removed and discarded, liquid was apirated and each 
well was washed 5 times with wash buffer. After the final wash, the plates were turn 
down and tapped to remove any residual liquid. 
Coloring: A 50 µl Chromogen A and 50 µl Chromogen B were added to each well 
including blank, mixed by tapping gently the plate. The plate was then incubated for 
15 minutes at temperature γ7 ◦C avoiding light. The chromogen solutions and HRP 
conjugate enzymatic reaction produced blue color in HAV-IgM positive samples and 
positive control.   
Stopping Reaction: A 50 µl volume of stop solution was added to each well and 
mixed gently. Intensive yellow color developed in HAV-IgM positive samples and 
positive control.   
Measuring the Absorbance: The absorbance was measured at 450nm against blank 
b. HBV ELISA Based Detection 
Reagents Preparation: All kit (HBsAg ELISA VERSION 1 Ref #: E0315) 
components were brought to room temperature (18-β5◦C) before use. Reagents were 
shaken gently. The one volume of wash solution was diluted with 19 volume of 
distilled/ deionized water and mixed well using magnetic stirrer. 
Measurement Procedure:  
The 50 µl of negative and positive control and samples were added to respected wells. 
Then 50 µl of enzyme conjugate was added to each well. The plate was then put on 
56 
 
shaker to shake for 30 seconds to mix the liquid completely within the wells. Plate was 
covered and incubated for γ0 minutes at γ7 ◦C temperature. Then γ50 µl of wash 
solution was added to each well, the plate was tapped and inverted to blot on blotting 
paper to remove any residual liquid. The process was repeated for 5 additional times. 
Then 50 µl of substrate A and then 50 µl of substrate B was added to each well. Gentle 
mixing was done for 15 seconds and incubation was done for 10 minutes at γ7 ◦C in 
dark place without shaking. Then 50 µl stop solution was added to each well and 
mixed gently for color production. The color was then noted and absorbance at 450 nm 
was read in microplate reader. 
c. HCV ELISA Based Detection 
Reagents Preparation: All kit (Anti-HCV ELISA VERSION 1 Ref #: E0320) 
components were brought to room temperature (18-β5◦C) before use. Reagents were 
shaken gently. “One part of wash solution was diluted with 1λ parts of distilled/ 
deionized water and mixed well using magnetic stirrer”. 
Measurement Procedure:  
A 100 µl of negative and positive control and sample diluents were added to respected 
wells. Then 10 µl of sample was added to the sample diluents containing wells. The 
plate was then put on shaker incubator for 30 seconds for complete mixing of the 
liquid within wells. Plate was covered and incubated for γ0 minutes at γ7 ◦C 
temperature. Then 350 µl of wash solution was added to each well, the plate was 
tapped and inverted to blot on blotting paper to remove any residual liquid. The 
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process was repeated for 5 additional times. Then 100 µl of enzyme conjugate was 
added to each well. The plate was covered and incubated for γ0 minutes at γ7 ◦C. Then 
350 µl of wash solution was added to each well, the plate was tapped and inverted to 
blot on blotting paper to remove any residual liquid. The process was repeated for 5 
additional times. Then 50 µl of substrate A and then 50 µl of substrate B was added to 
each well. Gentle mixing was done for 15 seconds and incubation was done for 10 
minutes at γ7 ◦C in dark place without shaking. Then 50 µl stop solution was added to 
each well and mixed gently for color production. The color was then noted and 
absorbance at 450 nm was read in microplate reader. 
d. HDV ELISA Based Detection 
Reagents Preparation: All kit (HDV Ab ELISA byDIA PRO Diagnostic Bioprobes, 
Srl., Italy) components were brought to room temperature (18-β5◦C) before use. 
Reagents were shaken gently. The 20x wash buffer (60mL) was diluted up to volume 
of 1200mL with double distilled water and mixed gently before use. 
Measurement Procedure:  
A 100 µl of negative control, positive control, calibrator and samples were added to 
respected wells. The microplate was then incubated for 60 minutes at γ7 ◦C. Then γ50 
µl of wash solution was added to each well, the plate was tapped and inverted to blot 
on blotting paper to remove any residual liquid. The process was repeated for 4 
additional times. Then 100 µl of enzyme conjugate was added to each well. The plate 
was covered and incubated for 60 minutes at γ7 ◦C. Then γ50 µl of wash solution was 
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again added to each well, the plate was tapped and inverted to blot on blotting paper to 
remove any residual liquid. The process was repeated for 5 additional times. Then 100 
µl of chromogen was added to each well. The microplate was then incubated for 20 
minutes at room temperature. Then 100 µl of 0.3M Sulphuric acid was added to the 
wells. Then 50 µl stop solution was added to each well and mixed gently for color 
production. The color was then noted and absorbance at 450 nm was read in 
microplate reader. 
e. HEV ELISA Based Detection 
Reagents Preparation: All kit (HEV IgM ELISA byDIA PRO Diagnostic Bioprobes, 
Srl., Italy) components were brought to room temperature (18-β5◦C) before use. 
Reagents were shaken gently. The 20x wash buffer (60mL) was diluted up to volume 
of 1200mL with double distilled water and mixed gently before use. 
Measurement Procedure:  
A 50 µl of neutralizing reagent was dispensed in all the wells of the samples. Then 100 
µl of each Samples (i.e., 1000 µl sample diluents+10 µl of the sample) was added in 
the respected wells, 100 µl of negative and positive control in their respected wells. 
The microplate was then incubated for 60 minutes at γ7 ◦C. Then γ00 µl of wash 
solution was added to each well, the plate was tapped and inverted to blot on blotting 
paper to remove any residual liquid. The process was repeated for 4 additional times. 
Then 100 µl of enzyme conjugate was added to each well. The plate was covered and 
incubated for 60 minutes at γ7 ◦C. Then γ50 µl of wash solution was again added to 
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each well, the plate was tapped and inverted to blot on blotting paper to remove any 
residual liquid. The process was repeated for 5 additional times. Then 100 µl of 
chromogen/substrate mixture was added to each well. The microplate was then 
incubated for 20 minutes at room temperature. Then 100 µl of 0.3M Sulphuric acid 
was added to the wells. The color was then noted and absorbance at 450 nm was read 
in microplate reader. 
2.6 EXPRESSION ANALYSIS 
A. Primer Designing 
Primers were designed specific to Interferon alpha receptor 1 and 2 sub-units and 
STAT 1 based on the previously known sequence as available on NCBI. Different 
bioinformatics tools including Oligo Calc: Oligonucleotide Properties Calculator 
(http://www.basic.northwestern.edu/biotools/oligocalc.html) and PrimerBank 
(http://pga.mgh.harvard.edu/primerbank/) were used for primer designing.  
Gene 
GenBank 
Accession 
Primer Sequence 
Size 
(bps) 
IFNAR1 NM_000629 
Forward 5’ AACAGGAGCGATGAGTCTGTC γ’ 
226 
Reverse 5’ TGCGAAATGGTGTAAATGAGTCA γ’ 
IFNAR2 NM_207585 
Forward 5’ ACAAGTGGCGGTGGCTATAC γ’ 
395 
Reverse 5’ TCAGGATCCTCTGGGTCAAC γ’ 
STAT1 NM_007315 
Forward 5’ GTCGGGGAATATTCAGAGCA γ’ 
198 
Reverse 5’ TGATCACTCTTTGCCACACC γ’ 
B. RNA Extraction and Reverse Transcription 
GeneJET™ RNA Purification Kit (Cat # #K07γ1, Fermentas) was used to purify total 
RNA. Before starting RNA purification, buffers were prepared as indicated in the kit. 
60 
 
Prior to first use, 10 ml volume of ethanol (96-100%) was added to 40 ml of Wash 
Buffer 1 (concentrated) and 39 ml of ethanol (96-100%) was added to 23 ml Wash 
Buffer 2 (concentrated). After the addition of ethanol, the check box was marked on 
the bottle’s cover in order to indicate the completed step. Before start of each RNA 
purification experiment, required amount of Lysis Buffer was supplemented with ȕ-
mercaptoethanol or DTT. To each 1 ml volume of Lysis Buffer, β0 µl of 14.γ M ȕ-
mercaptoethanol was added.  Before each use, Lysis Buffer was checked for salt 
precipitation and if present, re-dissolved by warming solution at 37°C and then cooled 
down to 25°C before use. The whole procedure was carried out under aseptic 
conditions and wear gloves.  
Total RNA Purification Protocol from Mammalian Tissue  
Before starting:  
The required amount of Lysis Buffer was supplement with ȕ-mercaptoethanol 
i.e., β0 µl of 14.γ M ȕ-mercaptoethanol was added to each 1 ml Lysis Buffer. The 
required amount of Proteinase K solution was prepared by diluting 10 µl Proteinase K 
to 590 µl TE buffer (APENDICE). 
Procedure: 
The sample was transferred to 1.5 ml Eppendorf and disrupted quickly by adding 
300 µl of Lysis Buffer (supplemented with ȕ-mercaptoethanol) and mixed thoroughly 
by vortexing for 10 seconds. A 600 µl volume of diluted Proteinase K i.e., 10 µl of 
Proteinase K in 590 µl of TE buffer was added to the lysate and mixed thoroughly by 
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vortexing. The tube was then incubated at 15-25°C for 10 min and centrifuge was done 
for 5 min (for lysate prepared from <10 mg of tissue sample) or 10 min (for lysate 
prepared from >10 mg of tissue) at a speed of ≥1β000 x g. The supernatant was 
transferred into new sterile (RNase-free) microcentrifuge tube, and 450 ȝl ethanol (λ6-
100%) was added and mixed by pipetting. Up to 700 ȝl of lysate was transferred to 
GeneJET RNA Purification Column that was inserted in a collection tube. 
Centrifugation was done for 1 min at a speed of ≥1β000 x g. The flowthrough was 
discarded and the purification column was place back into collection tube. This step 
was repeated until all the lysate was transferred into the column and centrifuged. The 
collection tube was discard that contained the flow-through. GeneJET RNA 
Purification Column was placed into a new 2 ml collection tube and 700 ȝl Wash 
Buffer 1 (that was supplemented with ethanol) was added to the GeneJET RNA 
Purification Column and centrifugation was done for 1 min at a speed of ≥1β000 x g. 
The flowthrough was discarded and purification column was placed back into the 
collection tube. Then 600 ȝl Wash Buffer β (also supplemented with ethanol) was 
added to the GeneJET RNA Purification Column and centrifugation was done for 1 
min at a speed of ≥1β000 x g. The flowthrough was discarded and purification column 
was placed back into the collection tube. The β50 ȝl Wash Buffer β was added to the 
GeneJET RNA Purification Column and centrifugation was done for 2 min at a speed 
of ≥1β000 x g. The collection tube was emptied and residual solution was removed 
from the purification column by re-spinning the column at maximum speed for 1 
minute. The collection tube was discarded which contained flow-through solution. The 
GeneJET RNA Purification Column was transferred to a new sterile RNase-free 1.5 ml 
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microcentrifuge tube and 50 ȝl of nuclease-free water was added to the center of the 
membrane of GeneJET RNA Purification Column and centrifugation was done for 1 
min at a speed of ≥1β000 x g to elute RNA. The purification column was discarded 
and purified RNA was stored at -80°C for cDNA synthesis. 
C. First Strand cDNA Synthesis  
The 1µg of total RNA isolated was then subjected to first strand cDNA synthesis 
using RevertAid Premium First Strand cDNA Synthesis Kit (#K1652, Fermentas). The 
kit components were thawed on ice and briefly centrifuged. The following reagents 
were added into a sterile (RNase free) tube placed on ice in the following order: 
 
 
 
 
 
 
 
Tube was mixed gently and centrifuged. For oligo(dT)18 primer/ gene-specific 
primer, tube was incubated for 30 minutes at 50°C. For random hexamer primer used, 
the tube was incubated for 10 minutes at 25°C and then for 30 minutes at 50°C. The 
Components Amount 
Total RNA 1 µg 
Oligo (dT)/ random hexamer primer/ 
gene-specific primer 
1µl (100 pmol) 
10 mM dNTP Mix 1 µl (0.5 mM final concentration) 
Nuclease-free Water 15 µl 
5X RT Buffer 4 µl 
RevertAid Premium Enzyme Mix  1 µl 
Total volume 20 µl 
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reaction was terminated by heating the tube for 5 minutes at 85°C. The first strand 
cDNA synthesis reaction product was directly used for PCR.  
D. PCR 
The product from first strand cDNA synthesis reaction was directly used in PCR. 
Normally 5 µl of first strand cDNA synthesis reaction product was used as template 
for subsequent PCR reactions of 50 µl total volume. Phusion High-Fidelity PCR 
Master Mix (Cat # F-531S, Fermentas) was used to amplify IFNAR1.  
Before opening, all the tubes were carefully mixed and centrifuged to ensure improve 
recovery and homogeneity. PCR reactions were always set up on ice. The components 
of the PCR were added in the order as follows: 
Components Amount 
H2O Upto 50 µl 
2x Phusion Master Mix 25 µl 
Forward Primer 0.5 µM (Final Concentration) 
Reverse Primer 0.5 µM (Final Concentration) 
Template (cDNA) 5 µl 
Total volume 50 µl 
 
The following same cycling conditions were used to amplify IFNAR1, 
IFNAR2 and STAT1 sequence from cDNA previously synthesized except the 
annealing temperatures which were different for all the three sequences.  
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Cycle Step Temperature Time Cycles 
Initial denaturation 98°C 5 minutes 1 
Denaturation 98°C 30 seconds  
 
30 
 
Annealing 
 
55°C for IFNAR1 
50°C for IFNAR2 
51°C for STAT1 
 
30~45 seconds 
Extension 72°C 30 seconds 
Final extension 72°C 
4°C 
10 minutes 
Hold 
1 
 
E. Agarose Gel Electrophoresis 
For visualizing the PCR products, 1.5 % agarose gel was used in tris-acetate-
EDTA (TAE) buffer (Appendix II). The samples were electrophoresed for 50 - 60 
minutes at 90 Volts. The gels were then stained in 0.1% ethidium bromide (EB) 
solution (Appendix II) and visualized using UV transilluminator. Bromophenol blue 
(BPB) 6x was always used as the loading/tracking dye.  DNA bands were compared 
with 1Kb DNA ladder to locate the positions of bands.  
2.7    STATISTICAL ANALYSIS 
Data obtained was analyzed statistically using SPSS Version 20 for 
significance. Percentages were calculated for categorical data. Variables were 
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compared among groups using ANOVA, chi-square statistics or Student's t-test as 
appropriate. The values were considered significant at 95% confidence interval.  
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Chapter 3 
RESULTS 
PART-1: QUALITATIVE RESEARCH 
HEPATITIS C VIRUS (HCV) AWARENESS   
The awareness study included normal subjects (n=14), subjects with HCV 
infection history (n=65 i.e., 15 responders to standard interferon treatment and 50 non-
responders to standard interferon treatment) and medical students (n=179). Normal 
subjects had age range between 21 and 59 years including 7 males and 8 females. 
Subjects with HCV infection history had age ranged between 25 and 74 years 
including 39 males and 26 females. Medical students had age range between 21 and 25 
years including 57 males and 122 females of MBBS and BDS from 3rd year and 4th 
year of different medical colleges from Rawalpindi and Islamabad. The subjects who 
refused to take part in the study were not included in the final data analysis.  
Regarding routes of HCV transmission, all subjects included in the study i.e., 
94.97% medical students, 98.46% HCV infected subjects and 100% healthy subjects 
were well aware of the blood and its products as source of HCV infection (Table 3, 
Graph 1). Medical students (94.41%) and healthy subjects (92.86%) as compared to 
HCV infected subjects (55.38%) were well aware of the fact that injection drug users 
(IDU) are at greater risk of getting HCV as compared to patients with HCV infection 
history.  There was confusion regarding sharing utensils as possible source of HCV 
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infection in all the groups i.e., only 51.40% medical students, 26.15% HCV infected 
subjects and 78.57% healthy subjects were aware.  
Medical students (77.65% and 85.47%) and healthy subjects (92.86%) were 
more knowledgeable regarding tooth brush and blade sharing as source of HCV 
infection compared to HCV infected subjects (53.85% and 60%) respectively. 
Regarding sexual contact as a source of HCV infection, 72.63% medical students, 
50.77% HCV infected subjects and 50% healthy subjects were aware.  Whereas for 
infected mother to baby as route of HCV transmission, 66.48% medical students, 
43.08% HCV infected subjects and 57.14% healthy subjects were aware.   
Subjects included in the study were also not well aware whether coughing & 
sneezing and saliva are sources of HCV infection or not i.e., only 54.75% medical 
students, 26.15% HCV infected subjects and 71.43% healthy subjects were aware that 
coughing sneezing is not source of HCV transmission whereas 27.37% medical 
students, 21.54% HCV infected subjects and 71.43% healthy subjects rule out saliva as 
route of HCV transmission. Regarding casual contact, patients had misperceptions 
(only 26.15% were aware) that once HCV is acquired, it will be transmitted to any 
other person who will be living with them. This was a major factor why most of the 
patients were depressed as relatives and friends were avoiding them. Most of the 
medical students (82.12%) and healthy subjects (71.43%) were aware that casual 
contact is not source of HCV transmission. Regarding re-use of syringe as a risk of 
HCV infection, 87.71% medical students, 66.15% HCV infected subjects and 85.72% 
healthy subjects were aware. Overall males were more knowledgeable as compared to 
females among all the groups included in the study.  
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Table 3: HCV Awareness Questionnaire and Medical Student’s Response (Percentage of correct answers) 
 
QUESTIONS 
Medical students 
n (%) 
Subjects with HCV infection history 
n (%) 
Healthy subjects 
n (%) 
Males 
(n=57) 
Females 
(n=122) 
Total 
(n=179) 
Males 
(n=39) 
Females 
(n=26) 
Total 
(n=65) 
Males 
(n=6) 
Females 
(n=8) 
Total 
(n=14) 
Blood/blood products 57 (100) 113 (92.62) 170 (94.97) 39 (100) 25 (96.15) 64 (98.46) 6 (100) 8 (100) 14 (100) 
Injection drug users 57 (100) 112 (91.80) 169 (94.41) 23 (58.97) 13 (50) 36 (55.38) 6 (100) 7 (87.5) 13 (92.86) 
Sharing utensils 36 (63.16) 56 (45.90) 92 (51.40) 12 (30.77) 5 (19.23) 17 (26.15) 5 (83.3) 6 (75) 11 (78.57) 
Sharing tooth brushes 57 (100) 82 (67.21) 139 (77.65) 22 (56.41) 13 (50) 35 (53.85) 6 (100) 7 (87.5) 13 (92.86) 
Sharing of blade 56 (98.25) 97 (79.51) 153 (85.47) 26 (66.67) 13 (50) 39 (60) 6 (100) 7 (87.5) 13 (92.86) 
Sexual contact 55 (96.49) 75 (61.48) 130 (72.63) 20 (51.28) 13 (50) 33 (50.77) 3 (50) 4 (50) 7 (50) 
Coughing and sneezing 50 (87.72) 48 (39.34) 98 (54.75) 14 (35.90) 3 (11.54) 17 (26.15) 4 (66.67) 6 (75) 10 (71.43) 
Casual contact 56 (98.25) 91 (74.59) 147 (82.12) 13 (33.33) 4 (15.38) 17 (26.15) 4 (66.67) 6 (75) 10 (71.43) 
Saliva 25 (43.86) 24 (19.67) 49 (27.37) 12 (30.77) 2 (7.69) 14 (21.54) 5 (83.3) 5 (62.5) 10 (71.43) 
Re-use of syringes 57 (100) 100 (81.97) 157 (87.71) 28 (71.79) 15 (57.69) 43 (66.15) 6 (100) 6 (75) 12 (85.72) 
Mother to baby 57 (100) 62 (50.82) 119 (66.48) 16 (41.03) 12 (46.15) 28 (43.08) 3 (50) 5 (62.5) 8 (57.14) 
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Graph 1: Graphical presentation of the awareness level of the subjects included in the study 
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SOCIO-ECONOMIC STATUS (SES) 
The cost for HCV diagnostics and treatment from different hospitals of 
Rawalpindi/ Islamabad was also approximately estimated in our study. The 
preliminary diagnostic tests for HCV (i.e., ELISA based detection, PCR based 
detection/ quantification, genotyping, liver function tests, etc) is above 200 USD i.e., 
equal to about average one month salary of a person in Pakistan. If the histopathology 
is included then it exceeds 300 USD. The standard IFN therapy costs more than 770 
USD. But pegylated interferon costs above 2500 USD. The treatment response 
monitoring costs more than 200 USD. In this scenario, the salary does not permit the 
person to undergo routine basic diagnostic tests to timely diagnose any infection/ 
disease. Treatment costs along with other charges including doctor’s fee, 
hospitalization and other expenses make the life of a person with average salary worst. 
Socioeconomic status of the patients was determined by considering three 
markers i.e., education, employment/ occupation and income.  
Educational level was categorized into 5 groups namely no-education, below 
matriculation, matriculation, graduation and post-graduation. About 92% of the males 
and ~80% of the females having HCV infection history either had no education or 
were metric/ below matric. About 67% males and ~75% females of healthy subjects 
were above matric in education. The education level was significantly different among 
groups (p < 0.05) as shown in Table 4 and Graph 2. The healthy subjects were 
significantly highly educated as compared to subjects with HCV infection history.  
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The subjects were also categorized based on the occupation. Among HCV 
infected patients including responders as well as non- responders, there were 
unemployed 11 individuals (10 males and 1 female) included in the study. Nine 
subjects were labors (all males), 6 healthcare staff persons (5 males and 1 female), 1 
businessmen (male), 1 student (female), 1 teacher (female), 2 drivers (males), 11 
government servants (all males), 1 shopkeeper (male) and 22 house wives. Among 
healthy subjects, 4 individuals were from health care staff (3 males and 1 female), 5 
students (2 males and 3 females), 3 teachers (1 male and 2 female) and 2 house wives 
were also included (as shown in Table 5 and Graph 3.) 
Income was classified PKR/ month in 4 categories: Level 1 (≤6000), β (6000-
20,000), 3 (20-40,000) and 4 (>40,000). Most of the HCV infected subjects included in 
the study had income 20,000 PKR/ month or less whereas most of healthy subjects had 
income level 20,000 or above PKR/ month (Table). The income for unemployed 
persons was marked zero unless they indicated some other source e.g., property 
benefits (hiring/ renting etc). Similarly house wives income was marked based on their 
husband’s income. The income difference among groups was also significant (p < 
0.05) as shown in Table 6 and Graph 4. 
RISK FACTORS FOR HCV INFECTION 
 In males with HCV infection history, visit to non-classified dentists and 
barber’s shaving were the high risk factors involved in acquiring HCV infection, 
whereas in females, surgical operations and blood transfusions were the most common 
possible routes of acquiring HCV. None of the case had tattoos or organ transplant in 
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our study. The other risk factors for males and females observed in the study include 
contact with needle pricks, sharing syringes, tooth brushes, history of cuts, hospital 
admissions and history of injections. Razor sharing, kidney dialysis and IDU were 
found to be particularly associated with the males. Body piercing was only observed in 
females (Table 7). 
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Table 4:  Educational level of the subjects included in the study 
 
 
 
 
 
 
 
Education 
level 
Subjects with HCV infection History n(%) Healthy Subjects n(%) 
Males 
(n=39) 
Females 
(n=26) 
Total 
(n=65) 
P value 
Males 
(n=6) 
Females 
(n=8) 
Total 
(n=14) 
P value 
No education 4 (10.26) 8 (30.77) 12 (18.46) 0.037 0 (0) 0 (0) 0 (0) NS 
Bellow Metric 9 (23.08) 4 (15.38) 13 (20) 0.448 0 (0) 1 (12.5) 1 (7.14) 0.369 
Metric 23 (58.97) 9 (34.62) 32 (49.23) 0.054 2 (33.33) 1 (12.5) 3 (21.43) 0.347 
Graduate 3 (7.69) 5 (19.23) 8 (12.31) 0.165 3 (50) 5 (62.5) 8 (57.14) 0.640 
Post graduate 0 (0) 0 (0) 0 (0) NS 1 (16.67) 1 (12.5) 2 (14.29) 0.825 
Education level No education Bellow Metric Metric Graduate Post graduate 
Subjects with HCV infection History  
vs 
Healthy Subjects (P values) 
0.081 0.253 0.0575 <0.001 0.002 
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Graph 2: Graphical presentation of the educational level of the subjects included in the study 
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Table 5:  Employment status of the subjects included in the study 
 
Subjects with HCV infection History 
n (%) 
Healthy Subjects 
n (%) 
 
P values 
Employment status 
Males 
(n=39) 
Females 
(n=26) 
Total 
(n=65) 
Males 
(n=6) 
Females 
(n=8) 
Total 
(n=14) 
Unemployed 10 (25.64) 1 (3.85) 11 (16.92) 0 (0) 0 (0) 0 (0) 0.097 
Labor 9 (23.08) 0 (0) 9 (13.85) 0 (0) 0 (0) 0 (0) 0.139 
Healthcare staff 5 (12.82) 1 (3.85) 6 (9.23) 3 (50) 1 (12.5) 4 (28.57) 0.048 
Businessman 1 (2.56) 0 (0) 1 (1.54) 0 (0) 0 (0) 0 (0) 0.640 
Student 0 (0) 1 (3.85) 1 (1.54) 2 (33.33) 3 (37.5) 5 (35.71) <0.001 
Teacher 0 (0) 1 (3.85) 1 (1.54) 1 (16.67) 2 (25) 3 (21.43) 0.002 
Driver 2 (5.13) 0 (0) 2 (3.08) 0 (0) 0 (0) 0 (0) 0.506 
Government servants 11 (28.21) 0 (0) 11 (16.92) 0 (0) 0 (0) 0 (0) 0.097 
Shopkeeper 1 (2.56) 0 (0) 1 (1.54) 0 (0) 0 (0) 0 (0) 0.640 
House wife N/A 22 (84.62)  N/A 2 (25)  0.001 
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Graph 3: Graphical presentation of the employment status of the subjects in the study 
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Table 6:  Income status of the subjects included in the study 
Monthly 
Income (in 
rupees) 
Subjects with HCV infection History  
n (%) 
Healthy Subjects  
n (%) 
p-value 
Males 
(n=39) 
Females 
(n=26) 
Total 
(n=65) 
Males 
(n=6) 
Females 
(n=8) 
Total 
(n=14) 
0 (No income) 6 (15.38) 0 (0) 6 (9.23) 0(0) 0(0) 0 (0) 0.237 
1 (≤6000) 12 (30.77) 7 (26.92) 19 (29.23) 0 (0) 0 (0) 0 (0) 0.020 
2 (6000-20,000) 9 (23.08) 13 (50) 22 (33.85) 2 (33.33) 2 (25) 4 (28.57) 0.703 
3 (20-40,000) 10 (25.64) 6 (23.08) 16 (24.62) 3 (50) 5 (62.5) 8 (57.14) 0.016 
4  (>40,000) 2 (5.13) 0 (0) 2 (3.077) 1 (16.67) 1 (12.5) 2 (14.29) 0.082 
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Graph 4: Graphical presentation of the income status of the subjects included in the study 
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Table 7:  Percentage of possible risk factors exposure in study subjects 
Groups Sex 
Blood 
transfusion 
Dental 
surgery 
classified 
Dental 
surgery 
non-classified 
Contact with 
blood/needle 
Sharing 
syringes 
sharing 
tooth 
brush 
sharing 
razor 
IDU 
Subjects with 
HCV infection 
history 
Males (n=39) 7 (17.95) 1 (2.56) 12 (30.77) 4 (10.26) 1 (2.56) 2 (5.13) 10 (25.64) 
2 
(5.13) 
Females (n=26) 7 (26.92) 1 (3.85) 2 (7.69) 1 (3.85) 1 (3.85) 1 (3.85) 0 (0) 0 (0) 
Healthy 
normal 
subjects 
Males (n=6) 1 (16.67) 2 (33.33) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Females (n=8) 0 (0) 1 (12.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Groups Sex 
Barber 
shave 
Surgical 
operation 
Blood loss 
due to accident 
History of Cut/ 
Major injury 
Ever 
admitted 
hospitals 
body 
piercing 
Injection 
history 
Kidney 
dialysis 
Subjects 
with HCV 
infection 
history 
Males (n=39) 10 (25.64) 2 (5.13) 7 (17.95) 1 (2.56) 9 (23.08) 0 (0) 9 (23.08) 2 (5.13) 
Females (n=26) 0 (0) 17 (65.38) 0 (0) 2 (7.69) 18 (69.23) 26 (100) 2 (7.69) 0 
Healthy 
normal 
subjects 
Males (n=6) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Females (n=8) 0 (0) 2 (25) 0 (0) 0 (0) 2 (25) 8 (100) 0 (0) 0 (0) 
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PART -11: QUANTITATIVE RESEARCH 
The quantitative research was conducted including 80 subjects (15 normal, 15 
responders to interferon treatment and 50 non-responders to interferon treatment). 
Their demographic as well as clinical parameters were analysed along with detection 
of liver expression of 3 genes IFNAR1, IFNAR2 and STAT. All the subjects included 
in the study were negative for ELISA based detection of HIV and viral hepatitis except 
group 3 which was only positive for HCV.  
  
 
Fig 10:  Subjects included in the study based on response to therapy 
3.1 AGE 
The study included 80 subjects with 15 normal, 15 responders to standard 
interferon treatment and 50 non-responders to standard interferon treatment. Normal 
subjects (group I) have age ranged between 21 and 59 years (mean of 36.6 ± 9.7 
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years), responders to standard IFN therapy (group II) have age ranged between 25 and 
46 years (mean of 34.9 ± 6.8 years) and non- responders (group III) included in the 
study have age ranged between 29 and 74 years (mean of 42.0 ± 11.2 years). Age was 
significantly different among the three groups (p = 0.032). Mean age of non-
responders was significantly higher than responders to IFN treatment (p = 0.005).  
There was no significant difference observed between the mean ages of normal vs 
responders (p = 0.59) and normal vs non-responders (p = 0.07) as shown in Table 8a 
and b, Graph 5. 
3.2 SEX 
Most of the patients non-responder to interferon treatment recruited randomly 
in the study were males (66%) i.e., 2:1 ratio of males as compared to females. Normal 
groups comprised of 46.7% males and 53.3% females and responders were 40% males 
and 60% females (Table 9 and Graph 6).   
3.3 Marital Status 
Most of the subjects as well as control subjects were married. Among the 
normal group, 66.7% subjects were married whereas 33.3% were unmarried. All 
subjects (100%) were married in control group 2 whereas 96% of the subjects included 
in the group 3 were married. The number of married subjects included in the study was 
significantly higher than single (Table 10, Graph 7). 
 
82 
 
3.4 Body Mass Index 
BMI of normal subjects (group I) ranged between 20.78 and 26.49 (mean of 
23.97 ± 1.76), responders to standard IFN therapy (group II) ranged between 21.53 and 
25.77 (mean of 22.95 ± 1.18) and non- responders (group III) ranged between 20.18 
and 34.67 (mean of 26.88 ± 3.20). Mean BMI of the non-responders falls in the 
overweight category. BMI was highly significantly different among the three groups (p 
< 0.001). Mean BMI of non-responders was significantly higher than responders to 
IFN treatment (p < 0.001) and normal healthy subjects (p < 0.001). No significant 
difference was observed between mean BMI values of normal and responders (Table 
11a and b, Graph 8).  
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Table 8a: AGE: Group Comparison via ANOVA between Normal, Responders and 
Non-Responders 
Groups N Mean Std. Deviation Minimum Maximum p-value 
Normal 15 36.60 ±9.66 21.00 59.00  
 0.032 Responders 15 34.93 ±6.80 25.00 46.00 
Non-responders 50 42.04 ±11.23 29.00 74.00 
Table 8b: AGE: Comparison between different groups along with their p-values 
Groups p-value 
Normal v Responders 0.590 
Normal v Non-responders 0.077 
Responders v Non-responders 0.005 
 
Graph 5: Age of the Subjects included in the study 
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Table 9: Sex of the Subjects included in the study 
 
 
 
 
Graph 6: Sex ratio of the Subjects included in the study 
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Table 10: Marital status of the Subjects included in the study 
Groups N Married Unmarried p-value 
1 15 10 (66.7%) 5 (33.3%)  
< 0.001 2 15 15 (100%) 0 (0%) 
3 50 48 (96%) 2 (4%) 
 
Graph 7: Marital status of the Subjects included in the study 
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Table 11a: BMI: Group Comparison via ANOVA between Normal, Responders and 
Non-Responders) 
Groups N Mean Std. Deviation Min. Max. p-value 
Normal 15 23.97 ±1.76 20.78 26.49  
< 0.001 Responders 15 22.95 ±1.18 21.53 25.77 
Non-responders 50 26.88 ±3.20 20.18 34.67 
Table 11b: BMI: Comparison between different groups along with their p-values 
Groups p-value 
Normal v Responders 0.072 
Normal v Non-responders < 0.001 
Responders v Non-responders < 0.001 
Graph 8: Body Mass Index of the Subjects included in the study 
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3.5 LIVER FUNCTION TESTS 
a. ALT 
ALT (U/l) of normal subjects (group I) ranged between 18 and 41 (mean of 
30.27 ± 7.87), responders to standard IFN therapy (group II) ranged between 22 and 56 
(mean of 37.93 ± 9.10) and non- responders (group III) ranged between 20 and 340 
(mean of 89.40 ± 66.60). ALT was highly significantly different among the three 
groups (p < 0.001). Mean ALT of non-responders was significantly higher than 
responders to IFN treatment (p < 0.001) and normal healthy subjects (p < 0.001). 
Significant difference was also observed between mean ALT values of normal and 
responders (p = 0.020) (Table 12a and b, Graph 9). 
b. ALP 
ALP (U/l) of normal subjects (group I) ranged between 104 and 356 (mean of 
217.3 ± 69.4), responders to standard IFN therapy (group II) ranged between 165 and 
348 (mean of 275.7 ± 52.6) and non- responders (group III) ranged between 56 and 
569 (mean of 182.3 ± 91.7). ALP was significantly different among the three groups (p 
= 0.001). Though, the mean values of all the groups were in normal range. Mean ALP 
of responders was significantly higher than non-responders to IFN treatment (p < 
0.001). Significant difference was also observed between mean ALP values of normal 
and responders (p = 0.015) but no significant difference was observed between normal 
and non-responders (p = 0.124). Significant difference was observed between 
responders and non-responders (p < 0.001) (Table 13a and b, Graph 10). 
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Table 12a: ALT (U/l): Group Comparison (ANOVA) between Normal, Responders 
and Non-Responders) 
Groups N Mean Std. Deviation Min. Max. p-value 
Normal 15 30.27 ±7.87 18.00 41.00  
< 0.001 Responders 15 37.93 ±9.10 22.00 56.00 
Non-responders 50 89.40 ±66.60 20.00 340.00 
Table 12b: ALT: Comparison between different groups along with their p-values 
Groups p-value 
Normal v Responders 0.020 
Normal v Non-responders < 0.001 
Responders v Non-responders < 0.001 
Graph 9: ALT of the Subjects included in the study 
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Table 13a: ALP: Group Comparison (ANOVA) between Normal, Responders and 
Non-Responders) 
Groups N Mean Std. Deviation Min. Max. p-value 
Normal 15 217.3 ± 69.4 104.00 356.00  
0.001 Responders 15 275.7 ± 52.6 165.00 348.00 
Non-responders 50 182.3 ± 91.7 56.00 569.00 
Table 13b: ALP: Comparison between different groups along with their p-values 
Groups p-value 
Normal v Responders 0.015 
Normal v Non-responders 0.124 
Responders v Non-responders < 0.001 
Graph 10: ALP of the Subjects included in the study 
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a. BILIRUBIN 
Bilirubin (mg/dL) of normal subjects (group I) ranged between 0.40 and 1.00 
(mean of 0.73 ± 0.18), responders to standard IFN therapy (group II) ranged between 
0.70 and 1.60 (mean of 1.03 ± 0.28) and non- responders (group III) ranged between 
0.50 and 2.10 (mean of 1.36 ± 0.41). Bilirubin was highly significantly different 
among the three groups (p < 0.001). Mean Bilirubin of non-responders was 
significantly higher than normal (p < 0.001) and responders to IFN treatment (p = 
0.001). Significant difference was also observed between mean Bilirubin values of 
normal and responders (p = 0.003) (Table 14a and 14b, Graph 11).  
3.6          Liver Ultrasound 
a. Liver Echo texture 
The liver echo texture was normal in all subjects included in group I and II. In 
group III, 18 (36%) patients have liver cirrhosis (Table 15, Graph 12).     
b. Spleen size 
The spleen size was normal in subjects included in group I and II. The increase 
in spleen size was observed in 16% of the non-responders and 44.4% of the non-
responders with cirrhotic liver (Table 16, Graph 13). 
c. Portal Vein Diameter (PVD) 
The PVD was normal in normal and responders groups but elevated in group 
III as compared to group I and II. PVD of normal subjects (group I) ranged between 
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0.90 and 1.10 (mean of 0.97 ± 0.07), responders to standard IFN therapy (group II) 
ranged between 0.90 and 1.10 (mean of 0.99 ± 0.07) and non- responders (group III) 
ranged between 0.90 and 1.40 (mean of 1.04 ± 0.14). PVD difference was insignificant 
among the three groups (p = 0.095). Mean PVD of non-responders was significantly 
higher than normal (p = 0.012) whereas in-significant as compared to responders to 
IFN treatment (p = 0.068). Mean PVD difference was also insignificant between 
normal and responders (p = 0.443) (Table 17a and 17b, Graph 14).  
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Table 14a: Bilirubin (mg/dL): Group Comparison (ANOVA) between Normal, 
Responders and Non-Responders) 
Groups N Mean Std. Deviation Min. Max. p-value 
Normal 15 0.73 ± 0.18 0.40 1.00  
 
< 0.001 
Responders 15 1.03 ± 0.28 0.70 1.60 
Non-
responders 
50 1.36 ± 0.41 0.50 2.10 
Table 14b: Bilirubin: Comparison between different groups along with their p-values 
Groups p-value 
Normal v Responders 0.003 
Normal v Non-responders < 0.001 
Responders v Non-responders 0.001 
Graph 11: Bilirubin of the Subjects included in the study 
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Table 15: Liver Echo texture of the Subjects included in the study 
 
 
 
 
 
Graph 12: Liver Echo texture of the Subjects included in the study 
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Table 16: Spleen size of the Subjects included in the study 
 
 
 
 
 
Graph 13: Spleen size of the Subjects included in the study 
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Table 17 a: Portal Vein diameter: Group Comparison (ANOVA) between Normal, 
Responders and Non-Responders) 
Groups N Mean Std. Deviation Min. Max. P-value 
Normal 15 0.97 ± 0.07 0.90 1.10  
0.095 Responders 15 0.99 ± 0.07 0.90 1.10 
Non-responders 50 1.04 ± 0.14 0.90 1.40 
Table 17 b: Portal Vein diameter: Comparison between different groups along with 
their p-values 
Groups P-value 
Normal v Responders 0.443 
Normal v Non-responders 0.012 
Responders v Non-responders 0.068 
Graph 14: PVD of the Subjects included in the study 
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3.7 EXPRESSION OF IFN RECEPTOR  
 Liver expression of IFNAR1, IFNAR2 and STAT1 was analyzed 
through qualitative PCR based detection method in HCV infected subjects non-
responder to standard interferon treatment. It was found that IFNAR1, IFNAR2 and 
STAT1 were expressed in 46% (23/50), 94% (47/50) and 98% (49/50) of the liver 
tissues of the non-responders. Biopsy samples were not available for normal healthy 
subjects as well as those subjects who responded to standard interferon treatment. 
Hence whole blood was used for PCR standardization and detection. It was found that 
all of the normal healthy subjects and responders to IFN standard treatment were 
expressing IFNAR1, IFNAR2 and STAT1.  
Eighteen patients (36%) among non-responders were cirrhotic and none of 
them was expressing IFNAR1. IFNAR2 was detected in 88.9% (16/18) and 96.9% 
(31/32) of cirrhotic and non-cirrhotic patients respectively. STAT1 was expressed in 
all patients except one cirrhotic patient (Table 18, Graph 15).  
Among non-responders, the patients expressing IFNAR1 (23/50) i.e., 46% 
were designated group 3a and the 27/50 patients (54%) who did not express IFNAR1 
were designated as group 3b. Significant difference was observed in age, BMI, ALT, 
ALP, bilirubin, portal vein diameter, viral load, liver histopathology (grade, stage and 
score) in patients who were negative for IFNAR1 expression as compared to positive 
one (summarized in table 21).  
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Table 18: IFNAR and STAT1 expression in the subjects included in study 
1.  
2.  
3.  
4.  
5.  
 
 
 
 
 
  
 
 
 
 
Groups N IFNAR1  
n (%) 
IFNAR2  
n (%) 
STAT1  
n (%) 
Normal 15 15 (100) 15 (100) 15 (100) 
Responders 15 15 (100) 15 (100) 15 (100) 
Non-
responders 
 
50 
23 (46) 47 (94) 49 (98) 
98 
 
 
 
 
 
 
 
Graph 15: IFNAR and STAT1 expression in the subjects included in study 
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3.8 VIRAL LOAD 
The viral load was not detected in normal and responders groups but elevated 
in group III. Magnitude of viral load was divided into 3 catagories according to Jensen 
(Jensen et al., 2006):  
1. Low (< 200,000 IU/mL), 
2. Intermediate (200,001-600,000 IU/mL) 
3. High (> 600,000 IU/mL) 
Regarding viral load, a trend was observed with respect to IFNAR1 expression. 
Most of the patients with positive liver expression have lower viral load as compared 
to the subjects negative for IFNAR1 expression. Whereas patients lacking the 
expression of IFNAR1 negative expression group had higher viral load. Similarly the 
liver cirrhosis patients also had higher viral loads as compared to non-cirrhotic patients 
(Table 19, Graph 16).   
3.9 Liver Histopathology 
Liver histopathology data showed that in all patients of interferon therapy non-
responders, inflammation (p < 0.001), fibrosis (p < 0.001) and overall score (p < 
0.001) of liver histopathology status was significantly worse in cirrhosis as compared 
to non-cirrhosis patients and IFNAR1 expression negative subjects as compared to 
positive subjects (Table 20a and b).   
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Table 19: Viral load of the Subjects included in the study 
Groups 
Non-responders 
n=50  
n (%) 
IFNAR1 Positive 
n=23 
n (%) 
IFNAR1 Negative 
n=27 
n (%) 
Cirrhosis Patients 
n=18 
n (%) 
Non cirrhosis  
Patients 
n=32 
n (%) 
Low 
(< 200,000 IU/mL), 
24 (48) 22 (95.65) 2 (7.41) 0 (0) 24 (75) 
Intermediate 
(200,001-600,000 IU/mL) 
11 (22) 1 (4.35) 10 (37.04) 6 (33.33) 5 (15.63) 
High 
(> 600,000 IU/mL) 
15 (30) 0 (0) 15 (55.56) 12 (66.67) 3 (9.38) 
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Graph 16: Viral load of the Subjects included in the study
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Table 20a: Liver Histopathology: Group Comparison via ANOVA 
Groups HAI Mean 
Std. 
Deviation 
Min. Max. 
Non-
responders 
n (50) 
Grade 6.40 ±2.03 4.00 10.00 
Stage 2.92 ±1.40 1.00 6.00 
Score 9.32 ±3.34 5.00 16.00 
IFNAR1 
Positive 
n (23) 
Grade 4.78 ±1.04 4.00 7.00 
Stage 1.91 ±0.29 1.00 2.00 
Score 6.70 ±1.11 5.00 9.00 
IFNAR1 
Negative 
n (27) 
Grade 7.78 ±1.60 4.00 10.00 
Stage 3.78 ±1.40 2.00 6.00 
Score 11.56 ±2.95 6.00 16.00 
Non-cirrhosis 
Patients 
n (32) 
Grade 5.06 ±1.05 4.00 7.00 
Stage 1.94 ±0.25 1.00 2.00 
Score 7.00 ±1.11 5.00 9.00 
Cirrhosis 
Patients 
n (18) 
Grade 8.78 ±0.73 8.00 10.00 
Stage 4.67 ±0.69 4.00 6.00 
Score 13.44 ±1.34 12.00 16.00 
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Table 20b: Liver Histopathology: Comparison between different groups included in 
the study 
Groups  P-value 
IFNAR1 Pos v IFNAR1 Neg  Grade < 0.001 
Stage < 0.001 
Score < 0.001 
Cirrhosis v Non cirrhosis Grade < 0.001 
Stage < 0.001 
Score < 0.001 
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Table 21: Comparison between Non responders IFNAR1 Positive group (3a) Vs Non    
Responders IFNAR1 Negative group (3b) 
 Group N Mean Std. Deviation p-value 
AGE 3a 23 37.09 ±6.76 
0.002 
3b 27 46.26 ±12.60 
BMI 3a 23 25.88 ±2.90 
0.038 
3b 27 27.74 ±3.25 
ALT 3a 23 52.87 ±25.80 
< 0.001 
3b 27 120.52 ±74.91 
ALP 3a 23 150 ±47.77 
0.015 
3b 27 209.82 ±110.53 
Bilirubin 3a 23 1.24 ±0.39 
0.054 
3b 27 1.46 ±0.40 
USpvdia 3a 23 0.99 ±0.09 
0.011 
3b 27 1.09 ±0.16 
Grade 3a 23 4.78 ±1.04 
< 0.001 
3b 27 7.78 ±1.60 
Stage 3a 23 1.91 ±0.29 
< 0.001 
3b 27 3.78 ±1.40 
Score 3a 23 6.70 ±1.11 
< 0.001 
3b 27 11.56 ±2.95 
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Chapter 4 
DISCUSSION 
Part I: Qualitative research 
HCV Awareness 
Hepatitis C virus (HCV) has infected ~170-180 million population worldwide 
(Houghton, 2009, Sulkowski et al., 2011, 2009) and Pakistan is amongst the high HCV 
prevalent countries (Martins et al., 2011).  
The predictable increase in mortality rate 2-3 fold in next two decades as result 
of potential HCV-mediated cirrhosis development will make it signature for liver 
transplantation. These data suggest how HCV is significantly important global public 
health problem (Szabo et al., 2003). In order to control HCV infection, health 
education and counseling is important along with testing of high risk population 
(Zanetti et al., 2003). In this regard, evaluation of level of awareness regarding routes 
of HCV transmission among population is essential. Hence keeping in view the high 
burden of HCV in Pakistan, this study was conducted to investigate the awareness 
level among subjects with HCV infection history, normal healthy individuals and 
medical students who are at the start of their clinical rotation. There are number of 
well known risk factors i.e., blood and related products and hence subjects included in 
the study were more aware of the blood and its products as potent routes of HCV 
transmission. Other risk factors were also important but they were ignored. Our 
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finding was similar to the survey conducted by Tiftikci et al., to evaluate the awareness 
regarding routes of HCV transmission among healthcare staff (including first-year and 
last-year medical students, dentists, pharmacists and nurses), hepatitis C infected 
patients and their household contacts in Turkey. It was found that HCV transmission 
by blood/blood products was well aware among the subjects included in the study 
whereas the other means of HCV transmission were either over-estimated or under-
recognized (Tiftikci et al., 2009).  Similarly earlier studies conducted in different 
regions of Pakistan also show that HCV awareness level is not adequate in Pakistani 
population (Jamil et al., 2010, Janjua and Nizamy, 2004).  We also observed same 
situation in subjects included in our study. Except the blood products as source of 
HCV transmission, other factors were either over-estimated or under-recognized. 
Medical students and healthy subjects were found to be more aware of the well known 
risks of acquiring HCV as compared to patients with HCV infection history.  The 
awareness level among HCV infected subjects was alarmingly low and this is the 
reason why they were not timely aware of their infection and the lack of knowledge 
can seriously pose threats to infection transmission to their close contacts.  
There was significant level of misconception observed in our study e.g., there 
is no evidence about association of casual contacts or sharing utensils with 
transmission of HCV (Lo Re and Kostman, 2005). Sneezing and coughing are also not 
the sources of HCV transmission (Arend, 2000). In a survey, 28% of the participants 
thought coughing or sneezing can transmit HCV from infected person to healthy one 
(Norton et al., 2014). In present study, we found subjects have misconceptions that 
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sharing utensil, casual contact and coughing and sneezing are the risks for acquiring 
HCV. This is alarming situation as if the medical students are not aware of the fact that 
casual contact/ sharing utensils/ sneezing coughing have not been associated with the 
HCV transmission then how will they treat the HCV infected patients efficiently. 
Similarly the knowledge is critically important for patients who suffer because of these 
misconceptions and their family and friends make the life tougher by minimizing 
contact with them. This leads to more depressing situation for the patients. Oral fluid 
mode of HCV transmission is a controversy (Suzuki et al., 2005) but saliva has been 
found positive for HCV in many studies (Arend, 2000, Suzuki et al., 2005). That’s 
why most of the subjects included in the study were also confused regarding salivary 
route of HCV transmission. 
In our study medical student who represent well educated part of society and 
are at the start of their clinical rotation, were found to be not well equipped to face the 
challenge being unaware of the knowledge they were supposed to be. Previous studies 
conducted regarding awareness among medical students in Pakistan also showed their 
inadequate level of knowledge. A survey was conducted in Karachi and their study 
showed that medical students entering into the professional life did not have sound 
knowledge of diseases such as Hepatitis and AIDS and the students need more 
education and emphasize to take universal precautions (Anjum et al., 2005). Another 
survey conducted in 3 medical colleges i.e., Rawalpindi Medical College, Islamic 
International Medical College and Shifa Medical College showed important 
shortcomings in the knowledge, attitude and practice of the medical students regarding 
HBV and HCV marking importance of further education of the students (Wajiha Raza, 
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2008). In a survey conducted at 7 dental schools of Taiwan, more than half of the 
Taiwanese dental students who participated in the study were not familiar to HCV 
infection (Hu et al., 2004). Students from Japan and France have shown that the 
students belonging to these developed countries have misconceptions with respect to 
their knowledge regarding infectious diseases i.e., HBV, HCV and HIV (Anjum et al., 
2005). In the present study, we also found that our medical students were not fully 
aware of HCV. Medical students are at higher risk of acquiring infections as they have 
direct contact with patients and they also deal with blood (transfusions), surgical 
instruments and injections. There is a need to start training regarding infectious 
diseases precautions in countries lacking safety equipment, safety instructions for 
infectious diseases and staff vaccination programmes (Anjum et al., 2005). 
In our study, the knowledge of the subjects included in the study was not 
satisfactory keeping in view the high prevalence of HCV infection in Pakistan. Overall 
patients infected with HCV had very little knowledge regarding routes of HCV 
transmission as compared to healthy subjects and medical students. Level of awareness 
was also lower among females in all groups as compared to males.   
Education regarding routes of HCV transmission among patients and their 
house hold contacts is critical to control HCV prevalence in general population. In 
adequate knowledge and spreading wrong information may result in unnecessary 
isolation of the chronically infected HCV patients leading to depression and social 
disgrace (Tiftikci et al., 2009). In Pakistan also, awareness programs are needed 
among general public to increase knowledge regarding HCV to make this society HCV 
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free for new generations and a comfortable place to live for healthy subjects as well as 
patients.  
Risk Factor Exposure among Subjects with HCV Infection History  
A number of risk factors are well known for transmitting HCV infection. 
Multiple risk factors can be found in a single person (Yee et al., 2001). In our study, 
we also found multiple risk factors for HCV infection in patients most prominent being 
unsafe medical practices i.e., surgical operation including dental surgery and 
injections.  About 65% of the women among HCV infected females had undergone 
surgery during delivering their babies. It is very serious situation as the threat is not 
only to the mother but also to the new born if the disease is not timely diagnosed. One 
of the mother included in the study acquired HCV infection during delivering her first 
baby through surgery. Days before delivering her second baby she came to know about 
her HCV infection through medical reports of hospital. She again had to undergo 
surgery for delivering her second baby and the second baby was found to be HCV 
infected. So it is alarming situation in Pakistani hospitals. It has been reported that in 
Pakistan’s highest populated province Punjab, the risk factors for HCV transmission 
include therapeutic injections (44.3%), dental surgery (16.6%) blood transfusion 
(10.7%) etc (Mujtaba et al., 2011). A study conducted in Turkey also found surgery as 
the most common factor for HCV transmission (Karaca et al., 2006).  Another study 
conducted in Egypt also observed unsafe medical practices as most common factor for 
HCV transmission (Reker and Islam, 2014). Unsafe injections and syringe reuse is 
unnecessarily common practice in Pakistan. Unnecessary injections are given because 
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of the concept and demand among patients that medicines via injection are more 
effective as compared to oral route.  (Altaf et al., 2004) . The second most frequent 
risk factor found in our study was body piercing which is very common in females 
especially earlobe piercing. None of males was found to have body piercing. In a study 
conducted in Brazil, one of the prominent risk factor for HCV was body piercing and 
women had more frequent body piercing as compared to males (Kvitko et al., 2013).  
In our study we found a number of risk factors responsible for HCV infection 
but unsafe medical practices are posing a serious threat to the society. There is a need 
to increase awareness among people regarding these risk factors. As part of awareness 
program, the participants of the study were briefed about what is HCV infection, its 
routes of transmission, signs and symptoms, diagnostic tests, and treatment options.   
Socio-Economic Status 
According to the Economic Survey (2013-14), 60.19% of the population is 
living below poverty line based on $2 per day set according to international standards 
for middle-income countries. This estimate is according to World Bank’s Poverty 
Head Count Analysis 2014. Poverty definition according to the Economic Survey of 
Pakistan is “a condition of person/community not having enough finances/resources 
and basics to maintain minimum life standard well-being that is acceptable in society”. 
Poverty is deprivation in well-being with low incomes, inability to access basic needs 
and services for survival with self-esteem. 
Poverty can also assessed as minimum number of calories taken/ with minimum 
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income satisfying necessary needs of a person/ day because 60% of the poor people’s 
budget spends on food etc (Kakakhel, 2014).  
We found that significant percentage of subjects with HCV infection history 
had low education level and living below poverty line (mostly jobless and depending 
on other means/ family members for their living and treatment) as compared to the 
healthy educated subjects. Low socio-economic status was found to be associated with 
high risk of HCV infection and poor prognosis in patients infected with HCV in 
Denmark , United States of America, Puerto Rico, France and Norway (Omland et al., 
2013). In our study, we also found the subjects infected with HCV have lower 
education, low income per month and low employment status suggesting the low 
socio-economic status as another risk factor. These results have implications clinically 
as well as with respect to public health.  People with low socio-economic status should 
be target for future studies with respect to HCV infection screening and other diseases 
as not only HCV, other diseases are also associated with people with low socio-
economic status (Omland et al., 2013).  
Part II: Quantitative research 
In Pakistan, about 6% of the population is victim of HCV with predominant 
genotype 3 (75–90% prevalence). Interferon alpha (IFN-α) plus ribavirin is widely 
used standard therapy for chronic HCV treatment all over the world but pegylated 
interferon along with Ribavirin has higher response rate than that of standard 
interferon. In Pakistan, standard interferon therapy is commonly given because of 
112 
 
economic reasons. Pakistan government is also providing only standard interferon 
through Prime Minister's initiative programme. But the actual response rate of the 
standard interferon is observed to be lower than previously reported (Ahmad et al., 
2012). Identifying the factors responsible for non-responsiveness can be helpful in 
predicting the treatment response. Resistance to therapy can be result of different 
factors including viral factors, host factors and HCV proteins induced molecular 
mechanism that inhibits IFN signaling cascade (Asselah et al., 2010). Hence in the 
current study we also focused on HCV genotype 3 infected patients. The patients were 
given twice course of therapy (24 weeks duration each) because of their non-response 
to first course of therapy and still high viral load observed. Now the question arises 
what can be the factors responsible for this unresponsiveness. 
Host factors also affect response to therapy e.g., age, gender, race/ ethnicity 
and clinical conditions like insulin resistance, diabetes, liver cirrhosis, steatosis, body 
mass index (BMI) (Asselah et al., 2010).  Some studies state both male and female are 
almost equally affected by the HCV and its genotypes (Ali et al., 2011, Qureshi et al., 
2009) whereas other studies suggest male sex association with high prevalence and 
poor response rate (Poynard et al., 1998). We have also observed more males infected 
by HCV genotype 3 and less responsive to interferon therapy.  
The Age (less than 35 years) is also a predictive factor for HCV treatment 
response to standard interferon alpha along with ribavirin in genotype 3 infected HCV 
patients (Bhutta S, 2011). According to Ahmed et al. (2009), in case of interferon 
standard therapy, age < 40 years is best predictive factor for sustained virological 
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response (Ahmed et al., 2011). Same observation was reported by Idrees and 
Riazuddin (2009) in their study conducted on 400 naïve chronic HCV infected patients 
(Idrees and Riazuddin, 2009). Our results also showed that the responders have an 
average age of about 35 years who responded to first course of IFN treatment as 
compared to the non-responders with the mean age of about 42 years who were non-
responders to twice course of interferon therapy.  
Some studies state both male and female are almost equally affected by the 
HCV and its genotypes (Ali et al., 2011, Qureshi et al., 2009) whereas other studies 
suggest male sex association with high prevalence and poor response rate (Poynard et 
al., 1998). We have also observed more males infected by HCV genotype 3 and less 
responsive to interferon therapy.  
BMI is another significant factor affecting SVR (Kim et al., 2012), our results 
showed that the normal controls as well as the responders have normal BMI as 
compared to the non-responders whose mean BMI falls in the overweight category 
hence increase in BMI is also associated with the failure to interferon therapy among 
HCV patients.  
We found that ALT and Bilirubin were significantly higher in HCV patients 
non-responders to interferon treatment as compared to the responders and the normal 
subjects. Elevated levels have been observed in non-responders to interferon treatment 
(Abbasi A, 2013). Initially normalization of ALT level was used to evaluate the 
treatment efficacy. Previous studies showed that ALT was found to be normal in 50% 
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of the patients treated with interferon but when therapy stopped, half of these patients 
had again elevated levels of ALT (Tong et al., 1997, Davis et al., 1989, Marcellin et 
al., 1991, Causse et al., 1991). Thus normal ALT rate (sustained biochemical response) 
was between 13-30% after 6 months of post-treatment.  Tong et al observed 19% of 
the patients had normal ALT levels (biochemical responders) after cessation of 
treatment but 40% of these biochemical responders were positive for HCV RNA 
(virological non-responders). Among virological responders (negative for HCV RNA) 
20% of responders had elevated ALT levels. So ALT level correlation with treatment 
efficacy have limitations, hence viral agent measurement is more reasonable and 
practical to determine treatment efficacy (Tong et al., 1997). We also found some 
mixed figures, 16% of the patients non-responders to interferon have normal ALT 
levels, whereas 40% of the responders had slightly elevated ALT levels. In our study, 
the levels of bilirubin were found to be normal in all groups though significant 
difference was observed among the mean values of all the groups.  Khan and Sarwar 
(2009) also found the normal levels of bilirubin among HCV infected patients 
subjected to interferon therapy (Khan and Sarwar, 2009).  
Among the viral factors affecting treatment response, HCV genotype and 
baseline viral load are important predictors of response to IFN alpha treatment and its 
duration (Asselah et al., 2010).  HCV patients have risk to develop other disorders that 
are costly in treatment with high morbidity rate e.g., cirrhosis and HCC (Kanwal et al., 
2011). Among them, cirrhosis develops as result of prolonged HCV infection (Seeff et 
al., 1992). In USA, the prevalence of cirrhosis among HCV infected patients was 
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found to be 18.5% in 2006 (Kanwal et al., 2011). The studies conducted by Khan et 
al., 2009, HCV is the leading cause of cirrhosis as 53.6% of the liver cirrhosis patients 
had anti HCV antibodies in their sera (Khan et al., 2009). In our study, 36% of the 
non-responders were found to have cirrhosis.   
IFNAR1 was detected in 23 out of 50 HCV patients resistant to interferon 
therapy showing interferon receptor expression, a significant factor, contributing to the 
resistance to the treatment. The mean age is younger in responders and normal as 
compared to the nonreponders. Liver histopathological grades, stages and scores were 
significantly different between nonresponders positive for intrahepatic IFNAR1 
expression as compared to non-responders negative for IFANR1 expression. Out of 50 
HCV patients non responders to standard IFN treatment, there were 18 patients with 
liver cirrhosis and were negative for intrahepatic IFNAR1 expression hence showing 
that the lack of expression may be the cause of advanced histopathological state of the 
liver and non-response to therapy. In addition to cirrhotic patients some of non-
cirrhotic patients non-responder to IFN treatment were also not producing IFNAR1. 
Hence IFNAR1 is found to be a major factor affecting treatment response in HCV 
patients in our study and disease severity. Our findings were similar to Chandra et al., 
who presented evidence that ER stress (induced by interference in ER functions) 
induced by HCV and autophagy results in degradation of IFNAR1 and other factors. 
They found 50% reduction in expression of IFNAR1 in liver biopsies of HCV infected 
chronic liver disease and IFNAR1 expression was impaired in almost all patients with 
liver cirrhosis. Reduction in IFNAR1 expression can be due to suppression of innate 
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immune response and progression of liver disease. Immune response suppression leads 
to carcinogenesis and hence can be the reason why cirrhosis is a risk for development 
of HCC. They also found that IFN- Ȝ receptor expression was not affected by HCV-
derived ER stress and autophagy suggesting the IFN-Ȝ treatment to overcome 
treatment resistance by HCV (Chandra et al., 2014). Our study is also supported by the 
studies conducted earlier (Salama H, 2007, Mathai et al., 1999, Morita et al., 1999, 
Massirer et al., 2004, Taylor et al., 2000, Gao et al., 2004). The importance of IFNAR1 
can be judged by the findings of the study conducted by Datta et al., 2011 (Datta et al., 
2011) that the full-length expression of IFNAR1 clone alone has the ability to restore 
defective signaling of Jak-Stat pathway, phosphorylation of Stat1-3, nuclear 
translocation and anti-HCV response in all cell lines resistant to IFN-α. The reason 
why 23 out of 50 HCV patients are positive for IFNAR1 mRNA expression but still 
resistant to interferon therapy is that there can be mutations in IFNAR1 sequence as 
has been observed in a study conducted by Naka et al 2005 (Naka et al., 2005a). Our 
studies show that lower expression of IFNAR1 is the reason responsible for interferon 
resistance in HCV patients and be considered a predictive factor for interferon 
resistance. 
However apart from IFNAR1, we also analyzed the qualitative expression of 
IFNAR2 in liver tissues. Almost all the patients expressed IFNAR2 and STAT1. Our 
study was consistent with that conducted earlier where IFNAR2 was expressed by 
90% of all the patients resistant to interferon therapy and hence is not major cause of 
resistance to therapy in HCV patients (Gulshan A. Trali et al., 2014).  Similarly 
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STAT1 is also expressed by responders as well responders and hence does not seem to 
be major cause of resistance to IFN therapy in HCV patients. These findings are 
similar to conducted by EL-Saadany but he found the main factor is STAT1 activation 
i.e., phosphorylation and hence STAT1 activation is important to conduct anti-viral 
actions and can be the treatment response predictor (El-Saadany et al., 2013) . 
According to Helbig et al, HCV genomic replicon blocked the IFN-α-induced STAT 
activation in hepatic cell line (El-Saadany et al., 2013, Helbig et al., 2008).  
There can be different elements associated with interferon resistance in HCV 
patients like viral and host factors and the HCV proteins triggered molecular 
mechanisms that play important role by inhibiting IFN stimulated signaling pathway 
(Asselah et al., 2010). Studies have suggested that HCV proteins are important HCV to 
evade from IFN response (El-Saadany et al., 2013). Low quality of interferon used for 
HCV treatment that compromises the costs can induce false/ pseudo interferon 
resistance.  
CONCLUSION 
IFNAR1 can be used as a predictor factor of response to IFN standard therapy 
as well as disease severity. The patients expressing IFNAR1 have better chances to 
respond to treatment. But in case of resistance to IFN-alpha, the alternative IFN- Ȝ 
treatment can be a good option. Our study also concludes that surgery/ medical 
malpractice is the major risk factor in our population. Besides the exposure to risk 
factors, awareness regarding HCV and low socioeconomic status also seem to be risk 
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factors for HCV in our study. There is inadequate awareness regarding HCV in 
Pakistani population. Measures should be taken to educate people regarding possible 
risks of acquiring HCV on urgent basis. It is time to educate the clinical students, 
patients, normal population regarding basic facts and figures about HCV so that they 
can better perform their role in preventing the transmission of this deadly disease. 
Policies should be approved at governmental level for timely diagnosis and prevention 
of this devastating virus. Socio-economic status should be considered another risk 
factor for acquiring HCV infection and future studies should target the low socio-
economic groups for research and other policies making purposes. 
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APPENDICES 
APPENDIX I: QUESTIONNAIRE 
Demographic data  
1. Name:  __________________________  2. Age:________   
3: Gender:_______  4: Marital status: ____________ 
Socio-Economic Status: 
1. Education:  
2. Employment/occupation:________________________ 
3. Income:______________________________________ 
Risk factors Exposed: 
Risk Factor Tick please 
1. Blood transfusion  
2. Dental surgery(Classified)  
3. Dental surgery (Non-classified)  
4. Contact with blood/needle   
5. Sharing syringes  
6. Sharing tooth brush  
7. Sharing razor  
8. IDU  
9. Barber shave  
10. Surgical operation  
11. Blood loss due to accident  
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12. History of cuts  
13. Ever admitted hospitals  
14. Body piercing  
15. History of injection  
16. Kidney dialysis  
 
Knowledge regarding HCV transmission sources 
Source of transmission Agree Disagree Have no 
idea 
1. Blood/ blood products    
2. Injection drug users    
3. Sharing utensils    
4. Sharing tooth brushes    
5. Sharing of blade    
6. Sexual contact    
7. Coughing and sneezing    
8. Casual contact    
9. Saliva    
10. Syringes    
11. HCV Infected Mother’s transferred the 
disease to baby 
   
 
 
127 
 
APPENDIX II 
AGAROSE GEL 
                 1.0 %  1.5 % 
Agarose                1.0 g  1.5 g 
1 % TAE buffer (pH 8.0)             100 ml  100 ml 
Agarose gel was dissolved by microwaving for 2 minutes, cooled to 50 ˚C and poured 
into the gel tray. 
50 X TRIS- ACETATE- EDTA (TAE) BUFFER 
Dissolve 242 gms of tris base, 57.1 ml of glacial acetic acid  and mix 100 ml of 0.5M 
EDTA (pH 8) in 500 ml of distilled water making the volume up to 1 liter and 1X 
concentration was used. 
     ETHIDIUM BROMIDE 
Ethidium bromide (1 percent)      10 ȝl 
Distilled water        100 ml 
Dissolve 1gm of ethidium bromide in 100ml of water and wrap the container in 
aluminum foil/ store in dark bottle. Store indefinitely at room temperature. 
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